nct_id stringlengths 11 11 | title stringlengths 23 300 | phase stringclasses 9
values | status stringclasses 13
values | study_type stringclasses 2
values | is_expanded_access bool 2
classes | sponsor stringlengths 5 100 | summary stringlengths 45 4.76k | interventions listlengths 1 12 | start_date stringlengths 0 10 | url stringlengths 44 44 | target_entities listlengths 0 5 | locations listlengths 0 104 | contact_phone stringlengths 0 29 | contact_email stringlengths 0 41 | eligibility dict | mechanism_summary dict |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT05031351 | NF-κB Inhibition in Amyotrophic Lateral Sclerosis | PHASE2 | UNKNOWN | INTERVENTIONAL | false | Sunnybrook Health Sciences Centre | This is a Phase II, single centre, randomized, parallel, double blind, placebo-controlled clinical trial to determine the safety of Withania somnifera in participants with Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DRUG",
"name": "Withania somnifera"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2021-10-19 | https://clinicaltrials.gov/study/NCT05031351 | [
"nf_b",
"neuroinflammation"
] | [
{
"facility": "Sunnybrook Health Sciences Centre",
"city": "Toronto",
"state": "Ontario",
"country": "Canada",
"status": "RECRUITING",
"lat": 43.70643,
"lon": -79.39864
}
] | 416-480-6100 | jake.wimmer@sri.utoronto.ca | {
"criteria": "Inclusion Criteria:\n\n* Diagnosed with laboratory supported probable, clinically possible, probable or definite ALS according to the World Federation of Neurology Revised El Escorial criteria (83) (Appendix A)\n* Disease duration from symptom onset no greater than 36 months at the Screening Visit\n* A... | {
"compound": "Withania somnifera",
"targeting_mechanism": "NF-κB inhibition to reduce neuroinflammation in ALS",
"targeting_mechanism_pmid": "28872464",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT03456882 | The Effect of RNS60 on ALS Biomarkers | PHASE2 | COMPLETED | INTERVENTIONAL | false | Mario Negri Institute for Pharmacological Research | Amyotrophic Lateral Sclerosis (ALS) is a rare lethal neurodegenerative disease involving inflammation. Riluzole, the only drug for ALS, improves median survival by 3 months. This prompts new treatments of ALS. RNS60 is an experimental drug with favorable effects in preclinical studies of neuroinflammation and neurodege... | [
{
"type": "DRUG",
"name": "RNS60"
}
] | 2017-05-30 | https://clinicaltrials.gov/study/NCT03456882 | [
"neuroinflammation",
"neurodegeneration"
] | [
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
},
{
"facility": "Azienda Opsedaliera Universitaria Consorziale Policlinico- Università degli studi di Bari",
... | {
"criteria": "Inclusion Criteria:\n\n1. Age 18 through 80 years inclusive;\n2. Geographically accessible to the site and able to come to the site once a week for 24 weeks;\n3. Definite, probable, probable laboratory supported ALS diagnosis according to the revised El Escorial criteria; 4) Disease duration 6 to 24 mo... | {
"compound": "RNS60",
"targeting_mechanism": "Reduces neuroinflammation and neurodegeneration",
"targeting_mechanism_pmid": "37433768",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT00919555 | Combination Therapy in Amyotrophic Lateral Sclerosis (ALS) | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Phoenix Neurological Associates, LTD | The purpose of the study is to determine the safety and the efficacy of Tretinoin and Pioglitazone HCL in patients with ALS who are currently on Riluzole. | [
{
"type": "DRUG",
"name": "Pioglitazone and Tretinoin"
},
{
"type": "DRUG",
"name": "Tretinoin and Pioglitazone HCL"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2008-06 | https://clinicaltrials.gov/study/NCT00919555 | [
"PPARγ",
"Retinoic acid receptors"
] | [
{
"facility": "Phoenix Neurological Associates, LTD",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
}
] | {
"criteria": "Inclusion Criteria:\n\n* El Escorial Classification of laboratory supported probable, probable, or definite ALS\n* Age 18 - 85 years\n* Male or female\n* FVC greater than or equal to 70% predicted\n\nExclusion Criteria:\n\n* Patients with FVC below 1.5 L or below 70% predicted\n* History of liver disea... | {
"compound": "Pioglitazone and Tretinoin",
"targeting_mechanism": "Pioglitazone acts through peroxisome proliferator-activated receptors (PPAR-γ) and modulates the hypothalamic melanocortin pathway; Tretinoin acts as a retinoid receptor agonist",
"targeting_mechanism_pmid": "26984187",
"animal_results": "Piogl... | ||
NCT07312240 | LONgitudinal and Integrated Evaluation of Biomarkers in reLation to phenotYpe in ALS | NA | RECRUITING | INTERVENTIONAL | false | Istituto Auxologico Italiano | Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive degeneration of upper and lower motor neurons, leading to paralysis and death. Despite its uniformly fatal outcome, ALS shows marked clinical heterogeneity with respect to phenotype, progression rate, cognitive involvement, ... | [
{
"type": "DIAGNOSTIC_TEST",
"name": "Lumbar Puncture for analysis of Cerebrospinal Fluid"
},
{
"type": "DIAGNOSTIC_TEST",
"name": "Deep Phenotyping"
},
{
"type": "DIAGNOSTIC_TEST",
"name": "Routine blood chemistry analysis and genetic analysis"
}
] | 2025-04-17 | https://clinicaltrials.gov/study/NCT07312240 | [] | [
{
"facility": "Istituto Auxologico Italiano IRCCS",
"city": "Milan",
"state": "Lombardy",
"country": "Italy",
"status": "RECRUITING",
"lat": 45.46427,
"lon": 9.18951
}
] | +3902619111 | f.verde@auxologico.it | {
"criteria": "Inclusion Criteria ALS patients:\n\n* diagnosis of Amyotrophic Lateral Sclerosis (ALS);\n* age ≥18 y;\n* feasibility of lumbar puncture (LP);\n* informed consent.\n\nExclusion Criteria ALS patients:\n\n* severe medical comorbidities;\n* recent traumatic, inflammatory, vascular, or neoplastic Central Ne... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT03652805 | A Study of IPL344 in the Treatment of ALS Patients | PHASE1, PHASE2 | SUSPENDED | INTERVENTIONAL | false | Immunity Pharma Ltd. | This is a prospective, open-label, phase 1/2a study, dose escalation, to evaluate tolerability, safety, and PK of I.V. administered IPL344 in participants with Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DRUG",
"name": "IPL344"
}
] | 2018-08-01 | https://clinicaltrials.gov/study/NCT03652805 | [] | [
{
"facility": "Hadassah Medical Center -Motor Neuron Disease Clinic",
"city": "Jerusalem",
"state": "",
"country": "Israel",
"status": "",
"lat": 31.76904,
"lon": 35.21633
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Male or female participants ages ≥18 to 80 years\n2. Consenting participants fulfilling the El Escorial criteria for probable and definite ALS (sporadic and familial)\n3. Participant has ALSFRS-R score \\>20, the latest ALSFRS-R test should be no more than 6 weeks before scree... | {
"compound": "IPL344",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04972487 | Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis | Expanded Access | APPROVED_FOR_MARKETING | EXPANDED_ACCESS | true | Biogen | The objective of this early access program (EAP) is to provide access to tofersen to eligible participants with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene prior to an alternative access mechanism in order to address a high unmet medical need in this populati... | [
{
"type": "DRUG",
"name": "Tofersen"
}
] | https://clinicaltrials.gov/study/NCT04972487 | [
"SOD1"
] | [
{
"facility": "Research Site",
"city": "Anchorage",
"state": "Alaska",
"country": "United States",
"status": "",
"lat": 61.21806,
"lon": -149.90028
},
{
"facility": "Research Site",
"city": "Los Angeles",
"state": "California",
"country": "United States",
"status"... | {
"criteria": "Key Inclusion Criteria:\n\n* Medically able to undergo the program procedures, as determined by the treating healthcare professional (HCP).\n* Weakness attributable to ALS and associated with a mutation in the SOD1 gene (SOD1-ALS).\n\nKey Exclusion Criteria:\n\n* Previous or current participation in a ... | {
"compound": "Tofersen",
"targeting_mechanism": "Antisense oligonucleotide targeting SOD1 mRNA to reduce mutant SOD1 protein expression.",
"targeting_mechanism_pmid": "37975798",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | |||
NCT00204464 | Study of the Effects Strengthening Exercises in Individuals With ALS | PHASE2 | COMPLETED | INTERVENTIONAL | false | University of Saskatchewan | Amyotrophic Lateral Sclerosis (ALS) is the most common motor neuron disease MND) among adults. Motor neurons in the spinal cord, brain stem, and cerebral motor cortex degenerate and create a variety of upper (UMN) and lower motor neuron (LMN) clinical signs and symptoms, with the most frequently presenting symptom bein... | [
{
"type": "PROCEDURE",
"name": "Exercise"
}
] | https://clinicaltrials.gov/study/NCT00204464 | [] | [
{
"facility": "Cleveland Clinic Foundation",
"city": "Cleveland",
"state": "Ohio",
"country": "United States",
"status": "",
"lat": 41.4995,
"lon": -81.69541
}
] | {
"criteria": "Inclusion Criteria:\n\n* definite and/or probable diagnosis of ALS\n* early stages of the disease\n\nExclusion Criteria:\n\n* history of neuromuscular dysfunction not related to ALS\n* active, confounding medical conditions\n* unwillingness or inability to comply with the protocol\n* FVC of less than 9... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | |||
NCT06256107 | Virtual Reality in Motor Neurone Disease | NA | COMPLETED | INTERVENTIONAL | false | Lancashire Teaching Hospitals NHS Foundation Trust | Motor Neurone Disease (MND) is a chronic progressive neurological condition where people experience weakness of muscles leading to pain and restriction of movement as well as problems with swallowing, breathing and communication. The purpose of this study is to establish if Virtual Reality is useful for people with MND... | [
{
"type": "DEVICE",
"name": "Virtual Reality Headset"
}
] | 2021-01-13 | https://clinicaltrials.gov/study/NCT06256107 | [] | [
{
"facility": "Lancashire Teaching Hospitals NHS Foundation Trust",
"city": "Preston",
"state": "",
"country": "United Kingdom",
"status": "",
"lat": 53.76282,
"lon": -2.70452
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Diagnosis of MND\n2. Sufficient cognitive ability to understand instructions with regards using the VR kit (ECAS score - minimum 100/136)\n3. Has sufficient motor ability/dexterity to use the kit or a carer who will be able to assist with the use of the kit.\n4. Can tolerate l... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04948645 | A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis | PHASE1 | TERMINATED | INTERVENTIONAL | false | AbbVie | Fosigotifator is an investigational drug being researched for the treatment of Amyotrophic Lateral Sclerosis. This is an up to 156-week, 2-part study. Part 1 will be a 4-week, randomized, double-blind, placebo-controlled study; Part 2 will be up to a 152-week active treatment extension (ATE) during which all subjects w... | [
{
"type": "DRUG",
"name": "Fosigotifator"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2021-09-22 | https://clinicaltrials.gov/study/NCT04948645 | [] | [
{
"facility": "UC Irvine Health ALS and Neuromuscular Center",
"city": "Irvine",
"state": "California",
"country": "United States",
"status": "",
"lat": 33.66946,
"lon": -117.82311
},
{
"facility": "Cedars-Sinai Medical Center",
"city": "Los Angeles",
"state": "California... | {
"criteria": "Inclusion Criteria:\n\n* Must have an identified, reliable caregiver.\n* Confirmed diagnosis of Familial Amyotrophic Lateral Sclerosis (ALS) or Sporadic ALS.\n* First ALS symptoms occurred \\<= 36 months before screening.\n* Able to swallow solids.\n* No known active COVID-19 infection at screening.\n*... | {
"compound": "Fosigotifator",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07169175 | A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS | PHASE1, PHASE2 | NOT_YET_RECRUITING | INTERVENTIONAL | false | SineuGene Therapeutics Co., Ltd. | The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy of SNUG01 in in adult subjects with Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DRUG",
"name": "SNUG01"
}
] | 2025-12-01 | https://clinicaltrials.gov/study/NCT07169175 | [] | [
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
},
{
"facility": "Peking University Third Hospital",
"city": "Beijing",
"state": "Beijing Municipality",... | +8617274855306 | patient@sineugene.com | {
"criteria": "* Key Inclusion Criteria\\*\\*:\n\n * Subjects who are able to provide written informed consent form (ICF).\n * Subjects who are males or females must be ≥ 18 years and ≤ 80 years of age at the screening visit.\n * Subjects who have clinically definite ALS, clinically probable ALS, or clinically pro... | {
"compound": "SNUG01",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT04428775 | A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease | PHASE2 | TERMINATED | INTERVENTIONAL | false | AZTherapies, Inc. | This is a Phase IIa, randomized, open-label, multi-center, multi-dose study for subjects with mild to moderate ALS. The protocol is designed to determine whether ALZT-OP1a treatment will positively impact neuro-inflammatory biomarkers and slow down or arrest functional decline in subjects with mild to moderate ALS. | [
{
"type": "DRUG",
"name": "ALZT-OP1a (cromolyn)"
}
] | 2020-09-08 | https://clinicaltrials.gov/study/NCT04428775 | [
"neuroinflammation"
] | [
{
"facility": "UCSD Altman Clinical and Translational Research Institute",
"city": "La Jolla",
"state": "California",
"country": "United States",
"status": "",
"lat": 32.84727,
"lon": -117.2742
},
{
"facility": "Mayo Clinic",
"city": "Jacksonville",
"state": "Florida",
... | {
"criteria": "Inclusion Criteria:\n\n* Male or female subjects aged 18-75 years, both inclusive;\n* Must provide written informed consent before any study related procedures;\n* Should be capable to complete all trial related procedures, assessments and visits in the judgement of Investigator;\n* Familial or sporadi... | {
"compound": "cromolyn (ALZT-OP1a)",
"targeting_mechanism": "Reduces neuroinflammation to slow or arrest functional decline in ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07567664 | Tracking and Predicting How Brain Damage Spreads in Neurodegenerative Diseases | NA | ENROLLING_BY_INVITATION | INTERVENTIONAL | false | IRCCS San Raffaele | Neurodegenerative diseases, including frontotemporal lobar degeneration (FTLD) spectrum syndromes, are characterized by the accumulation of insoluble protein aggregates in the central nervous system. A common feature of these diseases is that pathological changes accumulate over time following a stereotyped spatial pat... | [
{
"type": "DIAGNOSTIC_TEST",
"name": "3 Tesla MRI without contrast medium"
},
{
"type": "GENETIC",
"name": "Blood sample for genetic analysis"
},
{
"type": "DIAGNOSTIC_TEST",
"name": "Cerebrospinal fluid sampling (CSF)"
},
{
"type": "DIAGNOSTIC_TEST",
"name": "Neurologica... | 2017-06-01 | https://clinicaltrials.gov/study/NCT07567664 | [
"protein_aggregation"
] | [
{
"facility": "IRCCS San Raffaele",
"city": "Milan",
"state": "Lombardy",
"country": "Italy",
"status": "",
"lat": 45.46427,
"lon": 9.18951
}
] | {
"criteria": "Inclusion Criteria:\n\nAdult participants, under 85 years of age, diagnosed with bvFTD, semantic variant PPA, non-fluent variant PPA, PSP, CBS, and early-stage ALS, according to the criteria of Rascovsky (2011), Gorno-Tempini (2011), Litvan (1996), Armstrong (2013), and Brooks (2000), respectively;\n\n... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04797845 | Patient's TeleMonitoring With Amyotrophic Lateral Sclerosis Treated by Non Invasive Ventilation at Home. | NA | COMPLETED | INTERVENTIONAL | false | University Hospital, Toulouse | Single-center, prospective pilot study on patients with amyotrophic lateral sclerosis fitted with noninvasive ventilation. The objective is to assess the satisfaction of remote monitoring of patients on non-invasive ventilation after 12 months. | [
{
"type": "OTHER",
"name": "teleconsultation"
}
] | 2021-04-12 | https://clinicaltrials.gov/study/NCT04797845 | [] | [
{
"facility": "Toulouse University Hospital",
"city": "Toulouse",
"state": "",
"country": "France",
"status": "",
"lat": 43.60426,
"lon": 1.44367
}
] | {
"criteria": "o inclusion criteria:\n\n* Patient over 18 years,\n* Patient with Amyotrophic Lateral Sclerosis (ALS),\n* Already fitted by Non Invasive Ventilation (NIV),\n* Patient having signed the informed consent\n* Patient affiliated to a social security scheme,\n* Patient with a correct understanding of the Fre... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06429735 | Precise Robotically IMplanted Brain-Computer InterfacE | NA | RECRUITING | INTERVENTIONAL | false | Neuralink Corp | The PRIME Study is a first-in-human early feasibility study to evaluate the initial clinical safety and device functionality of the Neuralink N1 Implant and R1 Robot device designs in participants with tetraparesis or tetraplegia. The N1 Implant is a skull-mounted, wireless, rechargeable implant connected to electrode ... | [
{
"type": "DEVICE",
"name": "N1 Implant"
},
{
"type": "DEVICE",
"name": "R1 Robot"
}
] | 2024-01-09 | https://clinicaltrials.gov/study/NCT06429735 | [] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "RECRUITING",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of Miami",
"city": "Miami",
"state": "Florida",
"country": "United... | (877) 398-4465 | clinical-team-ct@neuralink.com | {
"criteria": "Inclusion Criteria:\n\n* Severe quadriplegia (tetraplegia) due to spinal cord injury or amyotrophic lateral sclerosis (ALS) for at least 1 year without improvement, where quadriplegia is defined as having very limited or no hand, wrist, and arm movement and all levels below\n* Life expectancy ≥ 12 mont... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT00635960 | Growth Hormone in Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | Federico II University | Several drugs have been proposed for ALS. These drugs included: Topiramate, Lamotrigine, creatine, Vit. E, Pentoxifylline, etc. Although most of the trials showed a positive trend, none of them reached a statistically significant result. The only exception is the Riluzole trial, that demonstrated a small but significan... | [
{
"type": "DRUG",
"name": "Growth Hormone (Somatropin)"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2007-03 | https://clinicaltrials.gov/study/NCT00635960 | [
"growth_hormone_signaling"
] | [
{
"facility": "Diparimento di Scienze Neurologiche",
"city": "Naples",
"state": "",
"country": "Italy",
"status": "",
"lat": 40.85216,
"lon": 14.26811
},
{
"facility": "Istituto Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche",
"city": "Naples",
"state": ""... | {
"criteria": "Inclusion Criteria:\n\n* Definite/probable ALS according to El Escorial criteria\n* Aged \\> 40, \\< 85 years\n* Progression from onset\n* Disease duration ≤3 years\n* Treatment with Riluzole\n\nExclusion Criteria:\n\n* Rapid disease progression in the first 6 months after diagnosis\n* Patients with tr... | {
"compound": "Somatropin (Growth Hormone)",
"targeting_mechanism": "Growth hormone (GH)/IGF-1 axis promotes neurotrophic and neuroregenerative effects in the CNS.",
"targeting_mechanism_pmid": "29149058",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_fr... | ||
NCT03887338 | Systematic Laryngoscopic Evaluation of Upper Airways in Ventilated ALS Patients in Portugal and in Norway | NA | UNKNOWN | INTERVENTIONAL | false | Tiina Maarit Andersen | The study examines if titration of Non-Invasive mechanical ventilation (NIV) settings during ongoing laryngoscopic visualization can improve the compliance of NIV in subjects with Amyotrophic Lateral Sclerosis (ALS). The study is a multicentre study between Norwegian National Advisory Unit on Long-term Mechanical Venti... | [
{
"type": "OTHER",
"name": "Transnasal Fiberoptic Laryngoscopy"
}
] | 2019-03-21 | https://clinicaltrials.gov/study/NCT03887338 | [] | [
{
"facility": "Norwegian National Advisory Unit on Long-term Mechanical Ventilation at Thoracic Department, Haukeland University Hospital",
"city": "Bergen",
"state": "Hordaland",
"country": "Norway",
"status": "",
"lat": 60.39299,
"lon": 5.32415
},
{
"facility": "Centro Hospital... | {
"criteria": "Inclusion Criteria:\n\n* Patients diagnosed Amyotrophic Lateral Sclerosis (ALS) due to El Escorial criteria\n* Must have already established Non-invasive ventilation (NIV)\n\nExclusion Criteria:\n\n* Ages under 18 years\n* Unstable ischemic heart disease\n* Oncological disease\n* Ventilatory support de... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT02590276 | Predict to Prevent Frontotemporal Lobar Degeneration (FDT) and Amyotrophic Lateral Sclerosis (ALS) | NA | COMPLETED | INTERVENTIONAL | false | Assistance Publique - Hôpitaux de Paris | The project focuses on C9orf72, the most frequent genetic form of frontotemporal dementias (FTD, or frontotemporal lobar degeneration, FTLD) and amyotrophic lateral sclerosis (ALS). FTD is the second commonest cause of degenerative dementia in presenium after Alzheimer's disease. Behavioural and cognitive impairments p... | [
{
"type": "BEHAVIORAL",
"name": "characterization"
}
] | 2015-10-08 | https://clinicaltrials.gov/study/NCT02590276 | [
"C9orf72"
] | [
{
"facility": "Groupe Hospitalier Pitié-Salpêtrière - Charles Foix",
"city": "Paris",
"state": "",
"country": "France",
"status": "",
"lat": 48.85341,
"lon": 2.3488
}
] | {
"criteria": "Inclusion Criteria:\n\n* Age ≥ 18\n* Signed informed consent for genetic and clinical study\n* To be carrier of a C9ORF72 mutation - Diagnosis criteria of FTD or ALS\n* To be French-speaking\n* To be affiliated to the social security scheme\n* Absence of another intercurrent neurological pathology (vas... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT00706147 | Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | University of Miami | The purpose of this study will be to demonstrate the safety, tolerability, and efficacy of arimoclomol in subjects with SOD1 positive familial Amyotrophic Lateral Sclerosis (ALS). This type of ALS is HEREDITARY (runs in families), and at least one other person in the family must have had ALS.
Study hypotheses: Arimocl... | [
{
"type": "DRUG",
"name": "Arimoclomol"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2009-01 | https://clinicaltrials.gov/study/NCT00706147 | [
"SOD1",
"heat_shock_response"
] | [
{
"facility": "University of Miami Miller School of Medicine",
"city": "Miami",
"state": "Florida",
"country": "United States",
"status": "",
"lat": 25.77427,
"lon": -80.19366
},
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
... | {
"criteria": "Inclusion Criteria:\n\n* Type of ALS that is hereditary (runs in families) only.\n* El Escorial criteria for familial ALS and a family history of a pathogenic mutation in a gene known to be associated with ALS, such as the SOD1 gene.\n* Willingness to undergo genetic testing and to learn the results.\n... | {
"compound": "Arimoclomol",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04380649 | Development and Test of a Headset for BCI Until Obtaining an Efficient and Comfortable System That Can be Used in Daily Practice by ALS People | NA | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | Centre Hospitalier Universitaire de Nice | "Brain-computer interfaces (BCIs) are computer-based systems that acquire brain signals, analyze them, and translate them into commands that are relayed to an output device to carry out a desired action. BCIs represent a very active and promising field of research among devices for people with severe motor disabilities... | [
{
"type": "DEVICE",
"name": "New headset prototype"
}
] | 2023-02-13 | https://clinicaltrials.gov/study/NCT04380649 | [] | [
{
"facility": "CHU de Nice",
"city": "Nice",
"state": "Provence-Alpes-Côte d'Azur Region",
"country": "France",
"status": "",
"lat": 43.70313,
"lon": 7.26608
}
] | {
"criteria": "Inclusion criteria\n\n1. Age ≥ 18 years old\n2. For women of childbearing potential, use of contraception for the duration of the study\n3. Diagnosis of suspected ALS, possible, probable with ENMG, probable, defined according to the criteria of the World Federation of Neurology (revised El Escorial cri... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT01622088 | Phase 3 Extension Study of Dexpramipexole in ALS | PHASE3 | TERMINATED | INTERVENTIONAL | false | Knopp Biosciences | The purpose of the study is to collect long-term safety data from subjects with Amyotrophic Lateral Sclerosis (ALS) exposed to dexpramipexole. | [
{
"type": "DRUG",
"name": "Dexpramipexole"
}
] | 2012-06 | https://clinicaltrials.gov/study/NCT01622088 | [
"mitochondrial_function"
] | [
{
"facility": "Barrow Neurological Institute - St. Joseph's Hospital",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of California at San Francisco - Fresno",
"city": "Fresno",
... | {
"criteria": "Inclusion Criteria:\n\n* Subject has the ability to understand the purpose and risks of the study and provide signed and dated informed consent (or have the consent confirmed by a witness if unable to write) and authorization to use protected health information (PHI) in accordance with national and loc... | {
"compound": "Dexpramipexole",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04518540 | Explore Neuroprotective Effect of Lipoic Acid in Amyotrophic Lateral Sclerosis | NA | UNKNOWN | INTERVENTIONAL | false | Second Affiliated Hospital, Zhejiang University, School of Medicine | In this proposed study, the investigators will evaluate the safety and efficacy of lipoic acid in treatment of Amyotrophic lateral sclerosis (ALS). The study will recruit 150 AD patients, and then these patients will be randomized to lipoic acid group or control group (75 patients per arm) for 6 courses for about 5 mon... | [
{
"type": "DRUG",
"name": "lipoic acid group"
},
{
"type": "DRUG",
"name": "control group"
}
] | 2020-09-01 | https://clinicaltrials.gov/study/NCT04518540 | [
"oxidative_stress"
] | [
{
"facility": "Second Affiliated Hospital,Zhejiang University School of Medicine",
"city": "Hangzhou",
"state": "Zhejiang",
"country": "China",
"status": "RECRUITING",
"lat": 30.29365,
"lon": 120.16142
}
] | 13646715353 | zhiyingwu@zju.edu.cn | {
"criteria": "Inclusion Criteria:\n\n1. Age range from 20 to 75 (including 20 and 75 years old), regardless of ethnic group or gender;\n2. The subjects should meet the diagnostic criteria for ALS by El Escorial revised criteria: \"Definite ALS\", \"Probable ALS\" and \"Probable, laboratory-supported ALS\".\n3. ALS F... | {
"compound": "lipoic acid",
"targeting_mechanism": "Antioxidant agent that reduces oxidative stress in neurodegenerative disease.",
"targeting_mechanism_pmid": "38473944",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT02118727 | Therapy in Amyotrophic Lateral Sclerosis (TAME) | PHASE2 | COMPLETED | INTERVENTIONAL | false | University of Kansas Medical Center | The purpose of this study is to determine if memantine at up to 20 mg twice a day when used in conjunction with riluzole, can slow down the disease progression of patients with ALS including potentially improving their neuropsychiatric changes, as well as determine if serum biomarkers can be used both as a diagnostic a... | [
{
"type": "DRUG",
"name": "Memantine"
},
{
"type": "DRUG",
"name": "Placebo (for Memantine)"
}
] | 2018-11-07 | https://clinicaltrials.gov/study/NCT02118727 | [
"NMDA receptor"
] | [
{
"facility": "Phoenix Neurological Associates",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "UC Irvine",
"city": "Irvine",
"state": "California",
"country": "United States",
... | {
"criteria": "Inclusion Criteria:\n\n1. Age 18-85\n2. Male or Female\n3. Clinically definite, probable, probable lab-supported, or possible ALS by El Escorial criteria\n4. ALSFRS-R \\> 25\n5. Must be willing to undergo longitudinal blood draws for biomarker analysis\n6. Availability and willingness to complete the s... | {
"compound": "Memantine",
"targeting_mechanism": "NMDA receptor antagonist that provides neuroprotection.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03068754 | Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS) | PHASE2, PHASE3 | TERMINATED | INTERVENTIONAL | false | Mallinckrodt | About 213 people with ALS will participate in this study. There will be locations in North and South America.
During the first part, participants will be randomly assigned to a group (like by flipping a coin). Out of every 3:
* 2 will get the study drug
* 1 will get a look-alike with no drug in it (placebo)
During t... | [
{
"type": "DRUG",
"name": "Acthar"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2017-06-22 | https://clinicaltrials.gov/study/NCT03068754 | [
"neuroinflammation"
] | [
{
"facility": "Neuromuscular Research Center",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Mayo Clinic - Arizona",
"city": "Scottsdale",
"state": "Arizona",
"country": "United St... | {
"criteria": "Inclusion Criteria:\n\n1. Is 18-75 years of age at Screening\n2. Has ALS symptom onset within 2 years prior to Screening\n3. Has forced vital capacity (FVC) no higher than 60% at screening\n4. If taking riluzole, is on a stable dose for 4 weeks before Screening\n\nExclusion Criteria:\n\n1. Has tracheos... | {
"compound": "Acthar (corticotropin)",
"targeting_mechanism": "Immunomodulatory agent that modulates neuroinflammation in ALS.",
"targeting_mechanism_pmid": "28872464",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03787420 | Development and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS. | NA | UNKNOWN | INTERVENTIONAL | false | Taipei Veterans General Hospital, Taiwan | This project aims to develop a smart communication system for patients with amyotrophic lateral sclerosis (ALS), especially for stage 3 and stage 4 (late stage). Patients with ALS will be able to communicate with outer environment by means of mental control or eye tracking control, which would increase their life quali... | [
{
"type": "OTHER",
"name": "communication system"
}
] | 2018-09-01 | https://clinicaltrials.gov/study/NCT03787420 | [] | [
{
"facility": "Cancer Center, Taipei Veterans General Hospital",
"city": "Taipei",
"state": "",
"country": "Taiwan",
"status": "RECRUITING",
"lat": 25.05306,
"lon": 121.52639
}
] | +8862-28757296 | cl_chou@vghtpe.gov.tw | {
"criteria": "Part one:\n\nInclusion Criteria:\n\n* ALS diagnostic criteria (Brooks et al., 2000).Must have the following characteristics:\n\n 1. Degeneration of motor neurons (LMN) by clinical, electrophysiological or neuropathological evidence.\n 2. Degeneration of upper motor neurons (UMN) is demonstrated by cl... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT01281189 | Phase 3 Study of Dexpramipexole in ALS | PHASE3 | COMPLETED | INTERVENTIONAL | false | Knopp Biosciences | The purpose of this study is to determine whether dexpramipexole (150 mg twice daily) is safe and effective in the treatment of Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DRUG",
"name": "Dexpramipexole"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2011-03 | https://clinicaltrials.gov/study/NCT01281189 | [
"mitochondrial_function"
] | [
{
"facility": "Barrow Neurological Institute - St. Joseph's Hospital",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of Arkansas for Medical Sciences",
"city": "Little Rock",
... | {
"criteria": "Inclusion Criteria:\n\n* Aged 18 to 80 years old, inclusive, on Day 1.\n* Diagnosis of sporadic or familial ALS.\n* Onset of first ALS symptoms within 24 months prior to Day 1.\n* World Federation of Neurology El Escorial criteria are met for a possible, laboratory-supported probable, probable, or defi... | {
"compound": "Dexpramipexole",
"targeting_mechanism": "Mitochondrial dysfunction modulator with neuroprotective properties.",
"targeting_mechanism_pmid": "35805131",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07533903 | Functional Outcomes and Control Using Synchron BCI - Australia | NA | RECRUITING | INTERVENTIONAL | false | Synchron, Inc. | Functional Outcomes and Control Using Synchron BCI - Australia (FOCUS-AUS) | [
{
"type": "DEVICE",
"name": "Stentrode"
}
] | 2026-05-22 | https://clinicaltrials.gov/study/NCT07533903 | [] | [
{
"facility": "The Royal Melbourne Hospital",
"city": "Melbourne",
"state": "",
"country": "Australia",
"status": "RECRUITING",
"lat": -37.814,
"lon": 144.96332
}
] | 323-796-2476 | clinical@synchron.com | {
"criteria": "Inclusion Criteria:\n\n1. Able to provide informed consent to participate in the study.\n2. Bilateral upper-limb paresis or Amyotrophic lateral sclerosis (ALS) with bilateral upper limb paresis\n3. The underlying condition causing motor impairment must be refractory to treatment and have been present f... | {
"compound": "Stentrode",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT00912041 | BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia | NA | RECRUITING | INTERVENTIONAL | false | Leigh R. Hochberg, MD, PhD. | The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts. | [
{
"type": "DEVICE",
"name": "Placement of the BrainGate2 sensor(s) into the motor-related cortex"
}
] | 2009-05 | https://clinicaltrials.gov/study/NCT00912041 | [] | [
{
"facility": "University of California, Davis",
"city": "Sacramento",
"state": "California",
"country": "United States",
"status": "RECRUITING",
"lat": 38.58157,
"lon": -121.4944
},
{
"facility": "Stanford University School of Medicine",
"city": "Stanford",
"state": "Cal... | 617-724-9247 | clinicaltrials@braingate.org | {
"criteria": "Inclusion Criteria:\n\n* Clinical diagnosis of spinal cord injury, brainstem stroke, muscular dystrophy, amyotrophic lateral sclerosis or other motor neuron disorders\n* Complete or incomplete tetraplegia (quadriplegia)\n* Must live within a three-hour drive of the Study site\n* (There are additional i... | {
"compound": "BrainGate2 sensor",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT00563537 | Molecular Imaging Modality by Positron Emission Tomography Using 18F-X : Study of Microglial Activation in Amyotrophic Lateral Sclerosis | PHASE1 | UNKNOWN | INTERVENTIONAL | false | University Hospital, Tours | PET imaging of activated microglia offers a tool of investigation of a range of brain diseases where neuroinflammation is a component.
Amyotrophic lateral sclerosis is the most frequent motoneuronal disease in adult.
This study was designed to explore the feasibility of molecular imaging modality by Positron Emission... | [
{
"type": "RADIATION",
"name": "18F-X PET SCAN"
}
] | 2007-01 | https://clinicaltrials.gov/study/NCT00563537 | [
"neuroinflammation"
] | [
{
"facility": "Service de Médecine Nucléaire et Ultrasons - Hôpital Bretonneau",
"city": "Tours",
"state": "Centre-Val de Loire",
"country": "France",
"status": "RECRUITING",
"lat": 47.39484,
"lon": 0.70398
}
] | (33) 2.47.47. 97.89 | roussel@med.univ-tours.fr | {
"criteria": "Inclusion Criteria:\n\n* suffering from probable or definite form of amyotrophic lateral sclerosis according to El Escorial criteria. Spinal or bulbar site of the disease.\n* Information and signature of the written consent form\n* French Social Security registration\n\nExclusion Criteria:\n\n* family ... | {
"compound": "18F-X PET imaging agent",
"targeting_mechanism": "PET imaging of activated microglia as an in vivo marker of microglial activation and neuroinflammation",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed... |
NCT07357428 | Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI) | NA | RECRUITING | INTERVENTIONAL | false | Paradromics | The Connect-One Study is an early feasibility study to obtain preliminary device safety information for the Connexus Brain-Computer Interface (BCI). The Connexus BCI is intended to be used as: (1) an assistive communication device to decode imagined language correlates and speech for patients with impaired communicatio... | [
{
"type": "DEVICE",
"name": "Connexus Brain-Computer Interface"
}
] | 2026-03-31 | https://clinicaltrials.gov/study/NCT07357428 | [] | [
{
"facility": "University of California, Davis",
"city": "Sacramento",
"state": "California",
"country": "United States",
"status": "RECRUITING",
"lat": 38.58157,
"lon": -121.4944
},
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts... | (512) 559 4120 | clinical-team@paradromics.com | {
"criteria": "Inclusion Criteria:\n\n* Clinical diagnosis of a progressive neuromuscular disease or a neurological injury.\n* Clinical diagnosis of anarthria or severe dysarthria.\n* Wheelchair dependent with severely impaired upper limb function.\n* Has a reliable method of communication and the ability to read and... | {
"compound": "Connexus Brain-Computer Interface",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT00125203 | Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | The University of Texas Health Science Center at San Antonio | The purpose of this study is to determine the safety and efficacy of Myobloc in ALS patients who are having excessive drooling.
The primary goal of the study is to determine if the patient perceives a benefit from the Myobloc in controlling excessive drooling. | [
{
"type": "DRUG",
"name": "Botulinum toxin type B (Myobloc)"
},
{
"type": "PROCEDURE",
"name": "Injection of salivary glands"
}
] | 2003-07 | https://clinicaltrials.gov/study/NCT00125203 | [
"acetylcholine_release"
] | [
{
"facility": "University of Kansas Medical Center/Neurology, 1008 Wescoe",
"city": "Kansas City",
"state": "Kansas",
"country": "United States",
"status": "",
"lat": 39.11417,
"lon": -94.62746
},
{
"facility": "Carolinas MDA Neuromuscular/ALS Center; Carolinas Medical System; 15... | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of probable or definite ALS based on current World Federation of Neurology criteria\n* Between the ages of 21-85, inclusive\n* Sialorrhea refractory to treatment with at least two anticholinergic medications OR has been intolerant of anticholinergic medications due to... | {
"compound": "Botulinum toxin type B (Myobloc)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT01641965 | Impact of Early Non Invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Patients | NA | COMPLETED | INTERVENTIONAL | false | Hospital Universitari de Bellvitge | Timing of initiating domiciliary no invasive ventilation (NIV) in amyotrophic lateral sclerosis patients remains unclear. The hypothesis of the study is that the early use of NIV, in the initial phase of respiratory muscle weakness, improves the prognosis of ALS patients.
Principal objective: To evaluate the impact of... | [
{
"type": "DEVICE",
"name": "Home pressure ventilator model Vivo 40 (BREAS Medical AB)"
}
] | 2012-04 | https://clinicaltrials.gov/study/NCT01641965 | [] | [
{
"facility": "Hospital Universitari Bellvitge",
"city": "L'Hospitalet de Llobregat",
"state": "Barcelona",
"country": "Spain",
"status": "",
"lat": 41.35967,
"lon": 2.10028
}
] | {
"criteria": "Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study\n* Definite ALS diagnosis according to El Escorial Criteria\n* Ability to understand and perform the pulmonary function test\n* FVC ≤ 75% (with FVC registry \\>75% documented within the six ... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT01160367 | Trial of Ascertaining Individual Preferences for Loved One's Role in End-of-Life | NA | COMPLETED | INTERVENTIONAL | false | Johns Hopkins University | Specific Aims and Hypotheses:
Aim 1: To test the effect of the "Trial of Ascertaining Individual preferences for Loved Ones' Role in End-of-life Decisions" (TAILORED) Intervention on family decision-making self-efficacy at 8 weeks both with respect to the patient's present situation and in a hypothetical situation in ... | [
{
"type": "OTHER",
"name": "TAILORED Patient Family Decision Making"
},
{
"type": "OTHER",
"name": "standard of care"
}
] | 2010-08-26 | https://clinicaltrials.gov/study/NCT01160367 | [] | [
{
"facility": "Johns Hopkins University",
"city": "Baltimore",
"state": "Maryland",
"country": "United States",
"status": "",
"lat": 39.29038,
"lon": -76.61219
}
] | {
"criteria": "Inclusion Criteria:\n\nPatient Inclusion Criteria\n\n1. Age 18 or older\n2. Speaks and reads English\n3. Diagnosed by a specialist at either Johns Hopkins Medical Institutions or University of Chicago Medical Center as having ALS or stage III or IV GI or pancreatic cancer.\n4. Accompanied to clinic by ... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04788745 | Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | The University of Queensland | MetFlex is an investigator led, open-label, single-arm, Phase 2a trial to determine the safety and tolerability of trimetazidine for the treatment of amyotrophic lateral sclerosis/motor neuron disease (ALS/MND). | [
{
"type": "DRUG",
"name": "Trimetazidine Dihydrochloride"
}
] | 2021-06-29 | https://clinicaltrials.gov/study/NCT04788745 | [
"metabolic_flexibility"
] | [
{
"facility": "Royal Brisbane & Women's Hospital",
"city": "Brisbane",
"state": "Queensland",
"country": "Australia",
"status": "",
"lat": -27.46794,
"lon": 153.02809
},
{
"facility": "University Medical Centre Utrecht",
"city": "Utrecht",
"state": "",
"country": "Net... | {
"criteria": "Inclusion Criteria:\n\n* Age between 18 and 75 years\n* Signed informed consent prior to the initiation of any study-specific procedures\n* Familial or sporadic ALS/MND, defined as clinically possible, probable, or definite as per the El Escorial criteria\n* Relative TRICALS risk score between -6.0 to ... | {
"compound": "Trimetazidine Dihydrochloride",
"targeting_mechanism": "Trimetazidine improves metabolic flexibility by modulating energy substrate utilization in motor neurons.",
"targeting_mechanism_pmid": "34783031",
"animal_results": "Trimetazidine treatment extended survival and delayed paralysis onset in S... | ||
NCT02479802 | Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | Instituto Grifols, S.A. | Pilot, phase II, prospective, open-label, uncontrolled study of plasma exchange with 5% albumin in 10 subjects having a definite, possible, or probable diagnosis of Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "BIOLOGICAL",
"name": "Albumin"
}
] | 2014-11 | https://clinicaltrials.gov/study/NCT02479802 | [] | [
{
"facility": "Hospital Universitari Bellvitge",
"city": "L'Hospitalet de Llobregat",
"state": "Barcelona",
"country": "Spain",
"status": "",
"lat": 41.35967,
"lon": 2.10028
}
] | {
"criteria": "Inclusion Criteria:\n\n* Signed written-informed consent.\n* Subjects over 18 years of age, and less than 70 years old.\n* Subjects with a definite, possible, or probable diagnosis of ALS, according to the revised El Escorial criteria.\n* Subjects having experienced their first ALS symptoms within 18 m... | {
"compound": "Albumin",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05889572 | Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With Amyotrophic Lateral Sclerosis | PHASE1 | COMPLETED | INTERVENTIONAL | false | MaaT Pharma | The purpose of this pilot study is to assess the safety and tolerability of multiple doses of MaaT033 in ALS patients and to analyze the gut microbiota composition and evolution before considering a larger randomized controlled efficacy study. | [
{
"type": "DRUG",
"name": "MaaT033"
}
] | 2023-06-08 | https://clinicaltrials.gov/study/NCT05889572 | [
"gut_microbiota"
] | [
{
"facility": "Centre Hospitalier Universitaire de Lille - CIC",
"city": "Lille",
"state": "",
"country": "France",
"status": "",
"lat": 50.63391,
"lon": 3.05512
},
{
"facility": "Hôpital de la Pitié-Salpêtrière - CIC Neuroscience",
"city": "Paris",
"state": "",
"coun... | {
"criteria": "Inclusion Criteria:\n\n* Male or female subjects aged between18 and 80 years\n* ALS meeting the revised El Escorial criteria for possible, probable, laboratory-supported probable, or definite ALS (familial or sporadic)\n* Time since first motor deficit at screening: at least 6 months, up to 24 months\n... | {
"compound": "MaaT033",
"targeting_mechanism": "MaaT033 is an oral microbiotherapy that modulates gut microbiota composition to reduce dysbiosis and intestinal inflammation associated with ALS.",
"targeting_mechanism_pmid": "28947596",
"animal_results": "Dysbiosis and increased intestinal permeability observed... | ||
NCT00330681 | Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) | PHASE3 | COMPLETED | INTERVENTIONAL | false | Shionogi | The primary objective of this study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip once a day in patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind, placebo-controlled manner. And in addition, this study ... | [
{
"type": "DRUG",
"name": "MCI-186"
},
{
"type": "DRUG",
"name": "Placebo of MCI-186"
}
] | 2006-05-31 | https://clinicaltrials.gov/study/NCT00330681 | [
"oxidative_stress"
] | [] | {
"criteria": "Inclusion Criteria:\n\n* Patients who are defined as \"definite ALS,\" \"probable ALS\" or \"probable-laboratory-supported ALS,\" met diagnostic criteria revised EL Escorial for Airlie House.\n* Patients who can eat a meal, excrete, or move with oneself alone, and do not need assistance in everyday lif... | {
"compound": "MCI-186",
"targeting_mechanism": "Antioxidant that reduces oxidative stress by neutralizing reactive oxygen species and maintaining the antioxidant system balance.",
"targeting_mechanism_pmid": "38473944",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
... | ||
NCT01806857 | Clinical Trial Nuedexta in Subjects With ALS | PHASE2 | COMPLETED | INTERVENTIONAL | false | Center for Neurologic Study, La Jolla, California, | The purpose of this study is to determine whether Nuedexta is effective in the treatment of symptoms (impaired speech, swallowing, and saliva control)associated with Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DRUG",
"name": "Nuedexta"
},
{
"type": "DRUG",
"name": "Matching Placebo"
}
] | 2013-04 | https://clinicaltrials.gov/study/NCT01806857 | [] | [
{
"facility": "California Pacific Medical Center",
"city": "San Francisco",
"state": "California",
"country": "United States",
"status": "",
"lat": 37.77493,
"lon": -122.41942
},
{
"facility": "Georgetown University Medical Center",
"city": "Washington D.C.",
"state": "Di... | {
"criteria": "Inclusion Criteria:\n\n* ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria\n* Age 18 years or older\n* Exhibits bulbar dysfunction manifested by dysarthria and/or dysphagia, according to PI judgment, exhibits a score of 55 or abov... | {
"compound": "Nuedexta",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00005674 | Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS] | PHASE2 | COMPLETED | INTERVENTIONAL | false | National Center for Research Resources (NCRR) | The purpose of this study is to evaluate the safety and effectiveness of creatine treatment in amyotrophic lateral sclerosis (ALS). There is currently no known effective treatment for ALS. It is known that nerve cells die in the brains and spinal cords of patients with ALS but the cause of the cell death is unknown. It... | [
{
"type": "DRUG",
"name": "Creatine"
}
] | https://clinicaltrials.gov/study/NCT00005674 | [
"cellular_energy_metabolism"
] | [
{
"facility": "Washington University",
"city": "St Louis",
"state": "Missouri",
"country": "United States",
"status": "",
"lat": 38.62727,
"lon": -90.19789
}
] | {
"criteria": "Inclusion Criteria:\n\n* A clinical diagnosis of definite, probably or laboratory supported probably ALS, either sporadic or familial ALS according to a modified El Escorial criteria\n* Willing and able to give informed consent\n* FVC greater than or equal to 50% predicted\n* Evidence of abnormality in... | {
"compound": "Creatine",
"targeting_mechanism": "Cellular energy metabolism enhancer that supports ATP production and mitochondrial function in motor neurons.",
"targeting_mechanism_pmid": "29549424",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_p... | |||
NCT02313402 | A New Eye-based Communication Device for ALS Patients | NA | COMPLETED | INTERVENTIONAL | false | Assistance Publique - Hôpitaux de Paris | Eighteen ALS patients will be trained to control a new communication device (Eye On Line: EOL) that permit over smooth eye movements to generate digits, letters, words or drawing at will. The intervention consists in a training program during six visits over 3 weeks on site allowing a gradual acquisition of the eye-wri... | [
{
"type": "DEVICE",
"name": "EOL (Eye On Line)"
}
] | 2014-06 | https://clinicaltrials.gov/study/NCT02313402 | [] | [
{
"facility": "Groupe Hospitalier Pitie Salpetriere",
"city": "Paris",
"state": "",
"country": "France",
"status": "",
"lat": 48.85341,
"lon": 2.3488
}
] | {
"criteria": "Inclusion criteria :\n\n* 18 to 65 years old\n* patient with SLA diagnosis\n* patient presenting writing troubles\n* patient with understandable speaking communication\n* patient with health insurance\n\nExclusion criteria :\n\n* patients presenting oculomotricity troubles\n* patients presenting fronto... | {
"compound": "EOL (Eye On Line)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT07688239 | The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab | PHASE2 | NOT_YET_RECRUITING | INTERVENTIONAL | false | Tiziana Life Sciences LTD | The goal of this clinical trial is to learn whether a nasal spray medicine called foralumab is safe and easy to tolerate in adults with amyotrophic lateral sclerosis (ALS). ALS is a disease that slowly damages the nerve cells that control movement, causing muscles to grow weaker over time. Foralumab is being studied as... | [
{
"type": "DRUG",
"name": "Foralumab Nasal"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2026-07-25 | https://clinicaltrials.gov/study/NCT07688239 | [
"neuroinflammation",
"immune_activation"
] | [] | {
"criteria": "Inclusion Criteria:\n\n* Adults ≥18 years of age and ≤75 years of age with a diagnosis of symptomatic ALS by revised El Escorial Criteria (clinically possible, probable, probable lab-supported, or definite).\n* Participant must be actively enrolled and must have met eligibility criteria for the Healey ... | {
"compound": "Foralumab Nasal",
"targeting_mechanism": "Immunomodulatory antibody that targets CD3 on T cells to reduce neuroinflammation and immune system activation in the CNS.",
"targeting_mechanism_pmid": "28872464",
"animal_results": "Tyrosine kinase inhibition with masitinib controlled microgliosis, neur... | ||
NCT01348451 | Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis | PHASE1 | UNKNOWN | INTERVENTIONAL | false | Neuralstem Inc. | This is a first-in-human trial of spinal derived stem cells transplanted into the spinal cord of patients with Amyotrophic Lateral Sclerosis (ALS). The goal of the study is to see if the cells and the procedure to transplant them are safe. | [
{
"type": "DEVICE",
"name": "surgical implantation"
}
] | 2009-01 | https://clinicaltrials.gov/study/NCT01348451 | [] | [
{
"facility": "Emory University",
"city": "Atlanta",
"state": "Georgia",
"country": "United States",
"status": "",
"lat": 33.749,
"lon": -84.38798
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Have the ability to understand the requirements of the study, provide written informed consent, understand and provide written authorization for the use and disclosure of Protected Health Information (PHI) \\[per Health Insurance Portability and Accountability Act (HIPAA) Priv... | {
"compound": "Human spinal cord-derived neural stem cells (neural progenitor cells)",
"targeting_mechanism": "Neural progenitor cells transduced to secrete GDNF, which provides neuroprotective support to motor neurons through glial differentiation and growth factor delivery.",
"targeting_mechanism_pmid": "360645... | ||
NCT02588677 | Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | AB Science | The objective is to compare the efficacy and safety of masitinib in combination with riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DRUG",
"name": "Masitinib (4.5)"
},
{
"type": "DRUG",
"name": "Riluzole"
},
{
"type": "DRUG",
"name": "Placebo"
},
{
"type": "DRUG",
"name": "Masitinib (3.0)"
}
] | 2013-04 | https://clinicaltrials.gov/study/NCT02588677 | [
"receptor_tyrosine_kinase"
] | [
{
"facility": "Hospital Carlos III",
"city": "Madrid",
"state": "",
"country": "Spain",
"status": "",
"lat": 40.4165,
"lon": -3.70256
}
] | {
"criteria": "Inclusion Criteria:\n\nMain inclusion criteria:\n\n1. Familial or sporadic ALS\n2. Patient diagnosed with probable of definite ALS\n3. Patient treated with a stable dose of riluzole (100 mg/day) for at least 30 days prior to screening\n\nExclusion Criteria:\n\n1\\. Patient who underwent tracheostomy an... | {
"compound": "Masitinib",
"targeting_mechanism": "Tyrosine kinase inhibitor that targets microgliosis and neuroinflammation by controlling aberrant glial cell activation.",
"targeting_mechanism_pmid": "27400786",
"animal_results": "Masitinib abrogated neuroinflammation, controlled microgliosis and aberrant gli... | ||
NCT01020331 | Memantine Therapy in Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | Phoenix Neurological Associates, LTD | Tau, a protein in the cerebrospinal fluid CSF is believed to be elevated in amyotrophic lateral sclerosis (ALS) patients. The investigators believe that Tau is truly a marker of increased neuronal death from any disease process. It is been shown that Memantine can inhibit and reverse the abnormal hyperphosphorylation o... | [
{
"type": "DRUG",
"name": "Memantine"
}
] | 2005-06 | https://clinicaltrials.gov/study/NCT01020331 | [
"glutamate_excitotoxicity"
] | [
{
"facility": "Phoenix Neurological Associates, LTD",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
}
] | {
"criteria": "Inclusion Criteria\n\n1. Age 18-85\n2. Male or Female\n3. Clinically definite ALS by El Escorial criteria\n4. Elevated levels of Tau in CSF\n\nExclusion Criteria:\n\n1. Patients with FVC below 1.5 L or who require respiratory assistance\n2. History of liver disease\n3. Severe renal failure\n4. History ... | {
"compound": "Memantine",
"targeting_mechanism": "NMDA receptor antagonist that inhibits and reverses abnormal hyperphosphorylation of tau, a cerebrospinal fluid marker of neuronal death.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",... | ||
NCT07478172 | Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease | NA | RECRUITING | INTERVENTIONAL | false | University of Missouri-Columbia | This single-arm pilot study evaluates the effects of whole-body electrical muscle stimulation (WB-EMS) exercise on neuromuscular and physical function in adults with neuromuscular disease (NMD). Due to motor unit impairments, NMD patients often cannot tolerate traditional exercise. WB-EMS bypasses voluntary activation ... | [
{
"type": "DEVICE",
"name": "Whole-body Electrical Muscle Stimulation Exercise"
}
] | 2026-03-10 | https://clinicaltrials.gov/study/NCT07478172 | [] | [
{
"facility": "NextGen Precision Health Building, Clinical and Translational Science Unit",
"city": "Columbia",
"state": "Missouri",
"country": "United States",
"status": "RECRUITING",
"lat": 38.95171,
"lon": -92.33407
}
] | 573-884-2596 | kristina.kelly@health.missouri.edu | {
"criteria": "Inclusion Criteria:\n\n* Age 18 or older\n* Diagnosed with one or more of the following neuromuscular conditions: Amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscle atrophy, spinal muscular atrophy, postpolio syndrome, inclusion body myositis, pompedisease, fascioscapulohumera... | {
"compound": "Whole-body electrical muscle stimulation (WB-EMS) exercise",
"targeting_mechanism": "Non-pharmacological intervention that directly stimulates muscle contractions by bypassing voluntary activation limits, compensating for motor unit impairments.",
"targeting_mechanism_pmid": "",
"animal_results":... |
NCT03508453 | IC14 for Treatment of Amyotrophic Lateral Sclerosis | PHASE2 | WITHDRAWN | INTERVENTIONAL | false | Implicit Bioscience | Fifty patients with amyotrophic lateral sclerosis that is progressing rapidly will be randomized to receive either the monoclonal antibody IC14 or placebo to be given intravenously over two hours twice weekly for 12 weeks. Blood and urine tests will be done to measure biomarkers in order to evaluate clinical response a... | [
{
"type": "BIOLOGICAL",
"name": "IC14"
},
{
"type": "OTHER",
"name": "Placebo"
}
] | 2021-08-15 | https://clinicaltrials.gov/study/NCT03508453 | [
"neuroinflammation"
] | [
{
"facility": "Royal Brisbane and Women's Hospital",
"city": "Herston",
"state": "Queensland",
"country": "Australia",
"status": "",
"lat": -27.44453,
"lon": 153.01852
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Signed informed consent prior to initiation of any study-specific procedures.\n2. Familial or sporadic MND defined as clinically possible, probable, or definite by Awaji-Shima Consensus Recommendations.\n3. Rapidly progressive MND as defined by a decline of 3 or more points in... | {
"compound": "IC14",
"targeting_mechanism": "Monoclonal antibody targeting complement component C5a receptor to reduce neuroinflammation and glial activation in ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pm... | ||
NCT04244630 | Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial | PHASE2 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | Dallas VA Medical Center | The purpose of this research is to investigate the validity of a previous clinical trial named EH301, which showed beneficial effects of anti-oxidant therapies in patients with amyotrophic lateral sclerosis (ALS). If validated by this study, providing over-the-counter anti-oxidants would be a simple, low risk, low-cost... | [
{
"type": "COMBINATION_PRODUCT",
"name": "Antioxidants"
}
] | 2023-11-02 | https://clinicaltrials.gov/study/NCT04244630 | [
"oxidative_stress"
] | [
{
"facility": "VA North Texas Health Care System",
"city": "Dallas",
"state": "Texas",
"country": "United States",
"status": "",
"lat": 32.78306,
"lon": -96.80667
}
] | {
"criteria": "Inclusion Criteria:\n\n1. A clinical diagnosis by a study investigator of laboratory-supported probable, probable, or definite ALS, according to a modified El Escorial criterion (Appendix 2).\n2. 21 to 80 years of age inclusive.\n3. If patients are taking riluzole for ALS, they must be on a stable dose... | {
"compound": "Antioxidants",
"targeting_mechanism": "Reduces oxidative stress by countering reactive oxygen species imbalance in motor neurons.",
"targeting_mechanism_pmid": "38473944",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""... | ||
NCT05442775 | A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) | PHASE3 | TERMINATED | INTERVENTIONAL | false | Cytokinetics | The purpose of this study is to assess the long-term safety and tolerability of reldesemtiv in patients with ALS who have successfully completed dosing in the Phase 3 clinical trial, CY 5031 (also known as COURAGE-ALS) | [
{
"type": "DRUG",
"name": "Reldesemtiv"
}
] | 2022-08-04 | https://clinicaltrials.gov/study/NCT05442775 | [
"neuromuscular_junction"
] | [
{
"facility": "St. Joseph's Hospital & Medical Center - Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of California Irvine - ALS & Neuromuscular Cent... | {
"criteria": "Inclusion Criteria:\n\n* Able to comprehend and willing to sign an ICF and willing to comply with all study procedures and restrictions for the duration specified in the Schedule of Activities. If non-written consent is given, a Legal Designee of the patient must sign the ICF form.\n* Completed dosing ... | {
"compound": "Reldesemtiv",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03168711 | Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Massachusetts General Hospital | This is a multi-center, 20-week study of inosine treatment.
Study Objectives and Endpoints The primary objective of the study is to determine the safety and tolerability of oral administration of inosine (administered daily) dosed to moderately elevate serum urate over 20 weeks.
The primary outcome measures will be
... | [
{
"type": "DRUG",
"name": "Inosine"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2017-10-01 | https://clinicaltrials.gov/study/NCT03168711 | [
"oxidative_stress"
] | [
{
"facility": "Holy Cross Hospital",
"city": "Fort Lauderdale",
"state": "Florida",
"country": "United States",
"status": "",
"lat": 26.12231,
"lon": -80.14338
},
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
"country": "U... | {
"criteria": "Inclusion Criteria:\n\n1. Age 18-85.\n2. Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria (Appendix 1).\n3. Slow vital capacity (SVC) ≥ 60% of predicted for age, height, and gender at the Screening Visit.\n4.... | {
"compound": "Inosine",
"targeting_mechanism": "Elevates serum urate to provide neuroprotection against oxidative stress in motor neurons.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05597436 | Intermediate-Sized Expanded Access Study | Expanded Access | NO_LONGER_AVAILABLE | EXPANDED_ACCESS | true | Seelos Therapeutics, Inc. | This expanded access protocol is to provide access to the investigational product, SLS-005, to participants with ALS who are not eligible to participate in clinical trials. | [
{
"type": "DRUG",
"name": "Trehalose"
}
] | https://clinicaltrials.gov/study/NCT05597436 | [
"protein_folding"
] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of California, Irvine",
"city": "Orange",
"state": "California",
"country": ... | {
"criteria": "Inclusion Criteria:\n\n1. Sporadic or familial ALS.\n2. Age 18 years or older.\n3. Cohort 1: Patients who do not qualify for any reasonably accessible ongoing clinical trial.\n4. Cohort 2: Patients who have completed the open label extension (OLE) period of Regimen E of the HEALEY ALS Platform Trial an... | {
"compound": "Trehalose",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | |||
NCT03573466 | Presymptomatic Neuromuscular Junction Defects and Compensatory Mechanisms in ALS | NA | UNKNOWN | INTERVENTIONAL | false | Assistance Publique - Hôpitaux de Paris | Denervation of neuromuscular junctions (NMJs) and initial compensatory reinnervation is the earliest pathological event in various motor neuron disease models, occurring far before motor symptom onset. In patients harboring genetic mutations responsible for Amyotrophic Lateral Sclerosis (ALS), identification of early, ... | [
{
"type": "PROCEDURE",
"name": "Muscle biopsy"
}
] | 2019-04-10 | https://clinicaltrials.gov/study/NCT03573466 | [] | [
{
"facility": "Pitié-Salpêtrière Hospital",
"city": "Paris",
"state": "",
"country": "France",
"status": "",
"lat": 48.85341,
"lon": 2.3488
}
] | {
"criteria": "Inclusion Criteria:\n\n* Subjects harboring a mutation in C9ORF72 or SOD1 gene\n* Without any functional motor complaint and clinical motor deficit at neurological examination\n* Aged 30 to 70 (inclusive).\n* Patients covered by the social insurance system\n\nExclusion criteria:\n\n* Any motor deficit\... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "Neuromuscular junction denervation and compensatory reinnervation occur before motor symptom onset in ALS mouse models (SOD1G93A).",
"animal_results_pmid": "30320556",
"repurposed_from": "not repurp... | ||
NCT02116634 | Mesenchymal Stem Cell Injection in Amyotrophic Lateral Sclerosis | PHASE1, PHASE2 | WITHDRAWN | INTERVENTIONAL | false | Alzahra Hospital, Iran | Whether the mesenchymal injection on ALS patients is effective or not? | [
{
"type": "BIOLOGICAL",
"name": "mesenchymal stem cell"
}
] | 2015-05 | https://clinicaltrials.gov/study/NCT02116634 | [
"neuroinflammation"
] | [
{
"facility": "Neurosciences Research Center",
"city": "Isfahan",
"state": "",
"country": "Iran",
"status": "",
"lat": 32.65246,
"lon": 51.67462
}
] | {
"criteria": "Inclusion Criteria:\n\n1. sporadic ALS according to escorial criteria\n2. onset of disease with spinal cord involvement, Less than 3 years of disease onset with disease progression at 6 past months\n3. mild to moderate spinal and bulbar disability,at least having score3 in swallowing, 2 in chewing and ... | {
"compound": "mesenchymal stem cell",
"targeting_mechanism": "Stem cells differentiate into support cells such as astrocytes, oligodendrocytes, or microglia, which produce growth factors and anti-inflammatory cytokines, provide nutrients, and buffer excessive glutamate to support degenerating motor neurons.",
"t... | ||
NCT07467746 | Research of Traditional Chinese Medicine Oral Preparation of C. Cicadae in the Treatment of ALS Patients With Elevated Plasma Sphingolipids | PHASE2 | NOT_YET_RECRUITING | INTERVENTIONAL | false | The Third Xiangya Hospital of Central South University | Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the degeneration of motor neurons, leading to progressive muscle weakness and functional decline. This study is designed as a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of... | [
{
"type": "DRUG",
"name": "C. cicadae"
},
{
"type": "DRUG",
"name": "Control"
}
] | 2026-04 | https://clinicaltrials.gov/study/NCT07467746 | [
"sphingolipid_metabolism"
] | [] | +8618975172668 | zhangruxu@vip.163.com | {
"criteria": "Inclusion Criteria:\n\n* Patients with ALS diagnosed according to the revised El Escorial criteria.\n* Significantly elevated plasma levels of key SL molecules (e.g., Cer(d18:0/24:0), Cer(d18:1/22:0), and other relevant molecules), meeting the predefined cut-off values for metabolic stratification.\n* ... | {
"compound": "C. cicadae",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT00812851 | Randomized Placebo-Controlled Crossover Trial With THC (Delta 9-Tetrahydrocannabinol) for the Treatment of Cramps in Amyotrophic Lateral Sclerosis (ALS) | NA | COMPLETED | INTERVENTIONAL | false | Cantonal Hospital of St. Gallen | Many patients with ALS experience cramps during the course of the disease. Frequently, cramps occur as the first symptom of the disease, months before the patients notice weakness and wasting. Cramp severity varies from mild, without affecting daily activities and sleep, to disabling, where almost any voluntary muscle ... | [
{
"type": "DRUG",
"name": "Dronabinol"
}
] | 2005-04 | https://clinicaltrials.gov/study/NCT00812851 | [
"Cannabinoid receptor"
] | [
{
"facility": "Kantonsspital St.Gallen",
"city": "Sankt Gallen",
"state": "",
"country": "Switzerland",
"status": "",
"lat": 47.42391,
"lon": 9.37477
}
] | {
"criteria": "Inclusion Criteria:\n\n* Patients must be at least 18 years of age and have full legal capacity\n* Patients must voluntarily give written informed consent\n* Patients diagnosed with possible, probable laboratory supported, probable or definite ALS according to the revised El Escorial criteria (Brooks 2... | {
"compound": "Dronabinol",
"targeting_mechanism": "Cannabinoids exert anti-excitotoxicity, anti-oxidant, and anti-inflammatory effects in motor neuron disease.",
"targeting_mechanism_pmid": "30520038",
"animal_results": "Preclinical studies in mice models of ALS using cannabinoid formulations have been publish... | ||
NCT03984708 | New Therapeutic Strategy in ALS Based on Metabolic Status and Associated Metabolic Pathways. | NA | COMPLETED | INTERVENTIONAL | false | University Hospital, Tours | Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects central and peripheral motor neurons. None of the clinical trials conducted have been clearly successful and the disease remains incurable, putting patients' vital prognosis at risk in the medium term. An alteration of the basal metabolism ... | [
{
"type": "OTHER",
"name": "Samples"
},
{
"type": "OTHER",
"name": "Indirect calorimetry"
},
{
"type": "OTHER",
"name": "Electrical bioimpedance"
}
] | 2020-01-27 | https://clinicaltrials.gov/study/NCT03984708 | [
"energy_metabolism"
] | [
{
"facility": "Neurology Department, University Hospital, Limoges",
"city": "Limoges",
"state": "",
"country": "France",
"status": "",
"lat": 45.83362,
"lon": 1.24759
},
{
"facility": "Neurology Department, University Hospitla, Tours",
"city": "Tours",
"state": "",
"c... | {
"criteria": "Case group selection criteria:\n\nInclusion Criteria:\n\n* Age ≥ 18 years and ≥ 75 years\n* ALS according to the El Escorial criteria\n* Diagnosis of ALS \\< 6 months\n* Symptoms onset \\< 2 years\n* Patients affiliated to social security scheme\n* Informed consent signed by the patient\n\nExclusion Cr... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06094205 | Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02) | NA | RECRUITING | INTERVENTIONAL | false | Leigh R. Hochberg, MD, PhD. | The goal of this study is to improve our understanding of speech production, and to translate this into medical devices called intracortical brain-computer interfaces (iBCIs) that will enable people who have lost the ability to speak fluently to communicate via a computer just by trying to speak. | [
{
"type": "DEVICE",
"name": "BrainGate Neural Interface System"
}
] | 2023-10-16 | https://clinicaltrials.gov/study/NCT06094205 | [] | [
{
"facility": "University of California, Davis",
"city": "Sacramento",
"state": "California",
"country": "United States",
"status": "RECRUITING",
"lat": 38.58157,
"lon": -121.4944
}
] | 617-724-9247 | lhochberg@mgh.harvard.edu | {
"criteria": "Inclusion Criteria:\n\n* Between 18 and 80 years of age\n* Clinical diagnosis of spinal cord injury, brainstem stroke, muscular dystrophy, amyotrophic lateral sclerosis or other motor neuron disorders\n* Complete or incomplete tetraplegia (quadriplegia)\n* Must live within a three-hour drive of the Stu... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT07023835 | Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis | PHASE2 | RECRUITING | INTERVENTIONAL | false | Zydus Therapeutics Inc. | Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis | [
{
"type": "DRUG",
"name": "50 mg Usnoflast"
},
{
"type": "DRUG",
"name": "75 mg Usnoflast"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2025-09-17 | https://clinicaltrials.gov/study/NCT07023835 | [
"usnoflast"
] | [
{
"facility": "Zydus US015",
"city": "La Jolla",
"state": "California",
"country": "United States",
"status": "RECRUITING",
"lat": 32.84727,
"lon": -117.2742
},
{
"facility": "Zydus US008",
"city": "Orange",
"state": "California",
"country": "United States",
"stat... | 6094534751 | fshaikh@zydustherapeutics.com | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of probable or definite Amyotrophic lateral sclerosis, according to the revised version of the El Escorial World Federation of Neurology criteria\n* Time since onset of first symptom of Amyotrophic lateral sclerosis ≤24 months. Date of Amyotrophic lateral sclerosis sy... | {
"compound": "Usnoflast",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT06169696 | EMPOWER Early Feasibility Study: Non-invasive BCI to Control a Wheelchair for People With Paralysis | NA | UNKNOWN | INTERVENTIONAL | false | Synaptrix Labs Inc. | Neuralis is an innovative assistive technology designed for individuals with severe neuromuscular conditions, enabling wheelchair control through EEG signals. This study aims to assess the safety, feasibility, and efficacy of Neuralis in restoring mobility and independence.
The device is a discreet EEG headset which s... | [
{
"type": "DEVICE",
"name": "Intervention/Treatment"
}
] | 2024-11 | https://clinicaltrials.gov/study/NCT06169696 | [] | [
{
"facility": "Synaptrix Labs",
"city": "New York",
"state": "New York",
"country": "United States",
"status": "",
"lat": 40.71427,
"lon": -74.00597
}
] | 5107099964 | aryan@synaptrix-labs.com | {
"criteria": "Inclusion Criteria:\n\n1. Severe quadriparesis\n2. Able to give consent\n3. Appropriate candidate for device\n4. Able and willing to access all clinical testing and not impeded by geographical location\n5. Proficient in English\n6. Have a study partner\n\nExclusion Criteria:\n\n1. History of seizures\n... | {
"compound": "Neuralis",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT07224269 | Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis | EARLY_PHASE1 | RECRUITING | INTERVENTIONAL | false | University of Iowa | This will be a single center, randomized, double-blind, placebo-controlled pilot study to assess the safety and tolerability of terazosin (TZ) at a dose of 5 milligrams (mg) per os (PO) daily for patients with amyotrophic lateral sclerosis (ALS). The primary outcome of this study is to determine whether TZ increases ad... | [
{
"type": "DRUG",
"name": "Terazosine"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2026-08-12 | https://clinicaltrials.gov/study/NCT07224269 | [
"atp_production"
] | [
{
"facility": "University of Iowa Health Care",
"city": "Iowa City",
"state": "Iowa",
"country": "United States",
"status": "RECRUITING",
"lat": 41.66113,
"lon": -91.53017
}
] | 319-356-8744 | emily-anderson@uiowa.edu | {
"criteria": "INCLUSION CRITERIA\n\n* Ages 18 - 80 years old\n* Diagnosed with ALS based on Gold Coast Criteria\n* ALS symptom onset within 36 months at enrollment\n* Slow vital capacity (SVC) greater than or equal to 60%\n* Riluzole use-Never taken or taking a stable dose for at least 4 weeks prior to screening vis... | {
"compound": "Terazosin",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT04762589 | RT001 in Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | Biojiva LLC | RT001-014 is a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects with Amyotrophic Lateral Sclerosis | [
{
"type": "DRUG",
"name": "RT001"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2021-03-10 | https://clinicaltrials.gov/study/NCT04762589 | [
"rt001"
] | [
{
"facility": "University of Tartu",
"city": "Tartu",
"state": "",
"country": "Estonia",
"status": "",
"lat": 58.38062,
"lon": 26.72509
},
{
"facility": "Riga Stradins Universtiy",
"city": "Riga",
"state": "",
"country": "Latvia",
"status": "",
"lat": 56.946,
... | {
"criteria": "Inclusion Criteria:\n\n1. Male or female subject with age 20 years to 75 years at the time of signed consent\n2. Patients who are defined as \"definite ALS,\" \"probable ALS\" or \"probable-laboratory-supported ALS,\" met diagnostic criteria revised EL Escorial for Airlie House.\n3. ALSFRS-R \\> 20\n4.... | {
"compound": "RT001",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06645197 | An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis | EARLY_PHASE1 | NOT_YET_RECRUITING | INTERVENTIONAL | false | Peking University Third Hospital | This is a multicenter, open-label, single-arm investigator-initiated clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of SNUG01 in patients with Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DRUG",
"name": "SNUG01"
}
] | 2024-10-16 | https://clinicaltrials.gov/study/NCT06645197 | [
"snug01"
] | [
{
"facility": "Peking University Third Hospital",
"city": "Beijing",
"state": "Beijing Municipality",
"country": "China",
"status": "",
"lat": 39.9075,
"lon": 116.39723
},
{
"facility": "Fujian Medical University Union Hospital",
"city": "Fujian",
"state": "Fuzhou",
"... | 15710013912 | neurbj@126.com | {
"criteria": "Inclusion Criteria:\n\n1.Able to understand and voluntarily sign the informed consent form, the informed consent form must be signed before performing any clinical trail procedures.\n\n2.18\\~80 years old (including 18 and 80 years old), both male and female. 3.Must have been diagnosed with clinically ... | {
"compound": "SNUG01",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT03828123 | Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Bioinova, s.r.o. | Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that targets motor neurons. Prognosis is invariably fatal within 3-5 years since manifestation of the disease. Despite improved understanding of the mechanisms underlying ALS, the treatment remains essentially only supportive and focused on ... | [
{
"type": "BIOLOGICAL",
"name": "Suspension of human autologous MSC 3P in 1.5 ml"
}
] | 2012-01 | https://clinicaltrials.gov/study/NCT03828123 | [
"neuroinflammation"
] | [] | {
"criteria": "Inclusion Criteria:\n\n1. established diagnosis of definite ALS according to El Escorial criteria\n2. riluzole naive or stable dose for at least 2 months,\n3. life expectancy more than 2 years\n4. patients able to provide written informed consent.\n\nExclusion Criteria:\n\n1. FVC less than 70%\n2. in c... | {
"compound": "Autologous multipotent mesenchymal stromal cells (MSCs)",
"targeting_mechanism": "MSCs reduce neuroinflammation and provide neuroprotection in ALS through modulation of immune responses and inflammatory signaling in the central nervous system.",
"targeting_mechanism_pmid": "27938483",
"animal_res... | ||
NCT00326625 | Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Teva Pharmaceutical Industries, Ltd. | Teva is developing 40 mg/ml Glatiramer Acetate (GA) Injection , administered once daily under the skin, for the treatment of ALS. The study drug is a higher dose formulation of Copaxone® (20 mg/ml GA), a marketed medication, approved for the treatment of relapsing-remitting multiple sclerosis. GA is an immunomodulating... | [
{
"type": "DRUG",
"name": "40 mg glatiramer acetate"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2006-07-27 | https://clinicaltrials.gov/study/NCT00326625 | [
"neuroinflammation"
] | [
{
"facility": "Teva Benelux",
"city": "Haarlem",
"state": "",
"country": "Belgium",
"status": "",
"lat": null,
"lon": null
},
{
"facility": "Teva Benelux",
"city": "Leuven",
"state": "",
"country": "Belgium",
"status": "",
"lat": 50.87959,
"lon": 4.70093
... | {
"criteria": "Inclusion Criteria:\n\n1. Diagnosis of definite or probable ALS in accordance with the El-Escorial criteria.\n2. Subject has experienced his/her first ALS symptoms within 3 years prior to the screening visit.\n3. Slow VC test equal or greater than 70% of the predicted value.\n4. The sum of the 3 respir... | {
"compound": "Glatiramer acetate",
"targeting_mechanism": "Glatiramer acetate is an immunomodulating drug that reduces inflammation and provides neuroprotection through modulation of immune responses in the CNS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repu... | ||
NCT01091142 | Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS) | PHASE1 | COMPLETED | INTERVENTIONAL | false | Neuraltus Pharmaceuticals, Inc. | Primary objectives: To assess the safety and tolerability of ascending doses of NP001 compared to placebo in subjects with ALS.
Secondary objective: To explore the effects of NP001 on biomarkers potentially relevant to ALS. | [
{
"type": "DRUG",
"name": "NP001"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2010-07 | https://clinicaltrials.gov/study/NCT01091142 | [
"neuroinflammation"
] | [
{
"facility": "California Pacific Medical Center",
"city": "San Francisco",
"state": "California",
"country": "United States",
"status": "",
"lat": 37.77493,
"lon": -122.41942
},
{
"facility": "University of Kansas Medical Center - Landon Center on Aging",
"city": "Kansas Cit... | {
"criteria": "Inclusion Criteria:\n\n* Males and females, age 21 years - 75 years\n* Subjects must be in generally sound health as appropriate for their ALS diagnosis.\n* Subjects must have a clinical diagnosis of laboratory-supported probable or definite ALS, according to modified El Escorial criteria.\n* Subjects ... | {
"compound": "NP001",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03293069 | Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | University Hospital, Lille | The alteration of iron metabolism is reported in animal models of amyotrophic lateral sclerosis (ALS) as well as in sporadic and genetic forms (SOD1 and C9orf72) of ALS. The high iron concentration of the brain, due to its high energy demand (high oxygen consumption), makes motor neurons particularly vulnerable to ener... | [
{
"type": "DRUG",
"name": "Deferiprone"
},
{
"type": "DRUG",
"name": "Placebo Oral Tablet"
}
] | 2019-01-30 | https://clinicaltrials.gov/study/NCT03293069 | [
"iron_metabolism",
"oxidative_stress"
] | [
{
"facility": "Chr Angers",
"city": "Angers",
"state": "",
"country": "France",
"status": "",
"lat": 47.47156,
"lon": -0.55202
},
{
"facility": "Chru Brest",
"city": "Brest",
"state": "",
"country": "France",
"status": "",
"lat": 48.39029,
"lon": -4.48628
... | {
"criteria": "Inclusion Criteria:\n\n* Categorized as; possible, laboratory supported probable, probable, or definite ALS (revised El Escorial criteria)\n* Spinal and bulbar forms of ALS\n* Duration of the disease of less than 18 months since the first symptoms of motor deficit or amyotrophy (isolated cramps or fasc... | {
"compound": "Deferiprone",
"targeting_mechanism": "Deferiprone is an iron chelator that reduces iron accumulation and associated oxidative stress in motor neurons, protecting against ferroptosis and iron-mediated neurodegeneration.",
"targeting_mechanism_pmid": "30266679",
"animal_results": "Iron accumulation... | ||
NCT07698496 | Evaluation of the Feasibility and Efficacy of a Chronic Brain-computer Interface for Speech Rehabilitation in Patients With Locked-in-syndrome (LIS) | NA | NOT_YET_RECRUITING | INTERVENTIONAL | false | University Hospital, Grenoble | Eighteen million people worldwide are affected by speech disorders. Locked-in syndrome (LIS) represents the most extreme form of communication disability resulting from motor impairment. In France, the Association du Locked-In Syndrome (ALIS) reports approximately 500 individuals with LIS, most of whom live at home. Th... | [
{
"type": "DEVICE",
"name": "Chronic speech BCI"
}
] | 2026-10-10 | https://clinicaltrials.gov/study/NCT07698496 | [] | [
{
"facility": "Hôpital Raymond Poincaré Garches",
"city": "Garches",
"state": "",
"country": "France",
"status": "",
"lat": 48.84226,
"lon": 2.18232
},
{
"facility": "Centre hospitalier Grenoble",
"city": "Grenoble",
"state": "",
"country": "France",
"status": "",... | (33) 456520389 | lafontanell@chu-grenoble.fr | {
"criteria": "Inclusion Criteria:\n\na. Male or female between 18 and 65 years old b. French speaking person c. Person in locked in syndrome with a severe speech disorder following either: i. A subcortical stroke ii. Amyotrophic Lateral Sclerosis. d. Person with stable clinical state (esp. regarding respiratory stat... | {
"compound": "Chronic brain-computer interface (BCI)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT05951556 | Telehealth Implementation of Brain-Computer Interface | NA | UNKNOWN | INTERVENTIONAL | false | Shirley Ryan AbilityLab | Determine if Telehealth intervention can allow/empower a caregiver (who is untrained) to effectively implement and utilize a Brain-Computer Interface for communication with a participant who is "Locked in" following progression of Amyotrophic Lateral Sclerosis and other conditions. | [
{
"type": "DEVICE",
"name": "Use of BCI"
}
] | 2021-09-30 | https://clinicaltrials.gov/study/NCT05951556 | [] | [
{
"facility": "ShirleyRyan AbilityLab",
"city": "Chicago",
"state": "Illinois",
"country": "United States",
"status": "RECRUITING",
"lat": 41.85003,
"lon": -87.65005
}
] | 312 238 2997 | ehitchcock@sralab.org | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis leading to severe communication impairment\n\nExclusion Criteria:\n\n\\-",
"sex": "ALL",
"min_age": "16 Years",
"max_age": "100 Years",
"healthy_volunteers": false,
"std_ages": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
} | {
"compound": "unknown",
"targeting_mechanism": "Brain-computer interface (BCI) enables communication by detecting brain signals and transforming them into useful commands to compensate for motor neuron loss.",
"targeting_mechanism_pmid": "32034787",
"animal_results": "unknown",
"animal_results_pmid": "",
"... |
NCT04768972 | FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS) | PHASE3 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | Ionis Pharmaceuticals, Inc. | The primary purpose of this study is to evaluate the efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS). | [
{
"type": "DRUG",
"name": "ION363"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2021-06-14 | https://clinicaltrials.gov/study/NCT04768972 | [
"FUS"
] | [
{
"facility": "University of California San Diego",
"city": "La Jolla",
"state": "California",
"country": "United States",
"status": "",
"lat": 32.84727,
"lon": -117.2742
},
{
"facility": "Stanford University Medical Center",
"city": "Palo Alto",
"state": "California",
... | {
"criteria": "Inclusion Criteria for Part 1:\n\n1. Participants must be ≥10 years of age at the time of informed consent and have signs or symptoms consistent with an ALS disease (in the opinion of the Investigator).\n2. Genetic mutation in FUS confirmed by a testing laboratory that is Clinical Laboratory Improvemen... | {
"compound": "ION363",
"targeting_mechanism": "ION363 targets FUS (fused in sarcoma) mutations that impair RNA binding and dynamic RNA interaction, causing aberrant phase separation and RNA processing defects in ALS.",
"targeting_mechanism_pmid": "31630970",
"animal_results": "unknown",
"animal_results_pmid"... | ||
NCT05003921 | Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injection for ALS | PHASE1 | SUSPENDED | INTERVENTIONAL | false | The Foundation for Orthopaedics and Regenerative Medicine | This trial will study the safety and efficacy of intrathecal injection of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of amyotrophic lateral sclerosis | [
{
"type": "BIOLOGICAL",
"name": "AlloRx"
}
] | 2025-12 | https://clinicaltrials.gov/study/NCT05003921 | [
"neuroinflammation"
] | [
{
"facility": "Medical Surgical Associates Center",
"city": "St John's",
"state": "",
"country": "Antigua and Barbuda",
"status": "",
"lat": 17.12096,
"lon": -61.84329
}
] | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of Amyotrophic Lateral Sclerosis.\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Anticoagulation medicine use\n* Clinically... | {
"compound": "AlloRx",
"targeting_mechanism": "Cultured allogeneic adult umbilical cord-derived mesenchymal stem cells delivered intrathecally to target neuroinflammation and support motor neuron survival in ALS.",
"targeting_mechanism_pmid": "29132389",
"animal_results": "Bone marrow-derived mesenchymal stem ... | ||
NCT04098406 | Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Clene Nanomedicine | The objective of this trial was to assess the efficacy, safety, and PK/PD effects of CNM-Au8 as a disease-modifying agent for the treatment of ALS by utilizing electrophysiological measures to detect preservation of motor neuron function. The primary endpoint was the mean change in the average difference between active... | [
{
"type": "DRUG",
"name": "CNM-Au8"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2019-12-19 | https://clinicaltrials.gov/study/NCT04098406 | [
"oxidative_stress"
] | [
{
"facility": "University of Sydney Brain and Mind Centre",
"city": "Sydney",
"state": "New South Wales",
"country": "Australia",
"status": "",
"lat": -33.86785,
"lon": 151.20732
},
{
"facility": "Westmead Hospital",
"city": "Sydney",
"state": "New South Wales",
"coun... | {
"criteria": "Inclusion Criteria:\n\n1. Able to understand and give written informed consent.\n2. Male or female patients aged 30 years or greater (inclusive) and less than 80 years of age at the time of Screening.\n3. Patients whose conditions are defined as possible or probable or definite ALS per the diagnostic c... | {
"compound": "CNM-Au8",
"targeting_mechanism": "CNM-Au8 acts as a nanocatalyst to reduce oxidative stress and preserve motor neuron function by modulating the antioxidant system and mitochondrial bioenergetics.",
"targeting_mechanism_pmid": "34198557",
"animal_results": "unknown",
"animal_results_pmid": "",
... | ||
NCT03481348 | Pharyngeal Electrical Stimulation in Amyotrophic Lateral Sclerosis | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | University of Ulm | During the course of ALS most patients develop swallowing deficits. In this pilot study we investigate if dysphagia in ALS can be improved by Pharyngeal Electrical Stimulation (PES). PES is Communauté Européenne (CE-) certificated and has been approved for treatment of neurological, oropharyngeal dysphagia. During PES,... | [
{
"type": "DEVICE",
"name": "Pharyngeal Electrical Stimulation"
}
] | 2018-02-01 | https://clinicaltrials.gov/study/NCT03481348 | [] | [
{
"facility": "University of Ulm",
"city": "Ulm",
"state": "",
"country": "Germany",
"status": "",
"lat": 48.39841,
"lon": 9.99155
}
] | {
"criteria": "Inclusion Criteria:\n\n* possible, probable or definite ALS according to the revised El Escorial criteria (Brooks et al. 2000)\n* age \\>18 years\n* able to understand all information and to give full consent according to good clinical practice (GCP)\n* moderate ot severe dysphagia, defined by a mean v... | {
"compound": "Pharyngeal Electrical Stimulation",
"targeting_mechanism": "Electrical stimuli applied via nasogastric tube at the pharynx to trigger reorganization processes in damaged brain structures and improve swallowing function in ALS-related dysphagia.",
"targeting_mechanism_pmid": "",
"animal_results": ... | ||
NCT03174938 | The Swedish BioFINDER 2 Study | NA | RECRUITING | INTERVENTIONAL | false | Skane University Hospital | The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g. to characterize the role of beta-amyloid pathology in early diagnosis of Alzheimer's disease (AD) using amyloid-PET (18F-Flutemetamol) and Aβ analysis ... | [
{
"type": "DIAGNOSTIC_TEST",
"name": "Flutemetamol F18 Injection"
},
{
"type": "DIAGNOSTIC_TEST",
"name": "[18F]-RO6958948"
},
{
"type": "DIAGNOSTIC_TEST",
"name": "Elecsys (Roche) Abeta42, Ttau and Ptau"
},
{
"type": "DIAGNOSTIC_TEST",
"name": "Lumipulse (Fujirebio) Abet... | 2017-05-15 | https://clinicaltrials.gov/study/NCT03174938 | [] | [
{
"facility": "Memory Clinic, Hospital of Ängelholm",
"city": "Ängelholm",
"state": "",
"country": "Sweden",
"status": "RECRUITING",
"lat": 56.2428,
"lon": 12.86219
},
{
"facility": "Memory Clinic, Skåne University Hospital",
"city": "Malmö",
"state": "",
"country": "... | +46 40 33 10 00 | erik.stomrud@med.lu.se | {
"criteria": "COHORT A: Cognitively healthy younger individuals (40-65 years of age) INCLUSION CRITERIA\n\n* Age 40-65 years\n* Absence of cognitive symptoms as assessed by a physician with special interest in cognitive disorders.\n* MMSE score 27-30 at screening visit.\n* Do not fulfill the criteria for MCI or any ... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT06877143 | Hypercaloric PEG Nutrition in ALS to Sustain Energy Homeostasis | NA | RECRUITING | INTERVENTIONAL | false | University of Ulm | Weight loss is a known negative prognostic factor in amyotrophic lateral sclerosis (ALS). Over the last years, various interventional studies targeting the energy deficit in ALS yielded promising results; however,it is still unclear which kind of nutrition or nutritional supplement is most beneficial. Moreover, there i... | [
{
"type": "DIETARY_SUPPLEMENT",
"name": "100% of individual calory requirement"
},
{
"type": "DIETARY_SUPPLEMENT",
"name": "120% of individual calory requirement"
}
] | 2025-03-01 | https://clinicaltrials.gov/study/NCT06877143 | [
"energy_metabolism"
] | [
{
"facility": "Ulm Universita, Department of Neurology",
"city": "Ulm",
"state": "Baden-Wurttemberg",
"country": "Germany",
"status": "RECRUITING",
"lat": 48.39841,
"lon": 9.99155
}
] | 0049 731 177 5374 | christine.herrmann@uni-ulm.de | {
"criteria": "Inclusion Criteria:\n\n* Possible, probable (clinically or laboratory) or definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria 1\n* Loss of ALS functional rating scale revised (ALSFRS-R) of ≥ 0.33 points per month since onset (first paresis) based on t... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT02891629 | Safety and Feasibility of the EyeControl Device | NA | COMPLETED | INTERVENTIONAL | false | Eyefree Assisting Communication Ltd | The EyeControl device is an eye movement-based communication device in the form of wearable glasses with connected infrared cam-era that tracks the pupil and translates blinks and movements into commands.This study is aimed to demonstrate the safety and feasibility of the EyeControl device in healthy volunteers, and AL... | [
{
"type": "DEVICE",
"name": "EyeControl device"
}
] | 2016-09 | https://clinicaltrials.gov/study/NCT02891629 | [] | [] | {
"criteria": "Inclusion Criteria:\n\n1. Subjects 18 to 65 years old\n2. Subject with understandable speaking communication\n3. Subject fluent in Hebrew (speech and writing skills)\n\n Additional inclusion criteria for Stage 2 of the study:\n4. Subjects with early stage ALS diagnosis - whose speech capability is un... | {
"compound": "EyeControl device",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04414345 | HEALEY ALS Platform Trial - Regimen C CNM-Au8 | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | Merit E. Cudkowicz, MD | The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Regimen C will evaluate the safety and efficacy of a single study drug, CNM-Au8, in participants with ALS. | [
{
"type": "DRUG",
"name": "CNM-Au8"
},
{
"type": "DRUG",
"name": "Matching Placebo"
}
] | 2020-07-30 | https://clinicaltrials.gov/study/NCT04414345 | [
"cnm_au8"
] | [
{
"facility": "Healey Center for ALS at Mass General",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
}
] | {
"criteria": "Inclusion Criteria:\n\n* No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683).\n\nExclusion Criteria:\n\n* The following exclusion criterion is in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683).\n\n 1. ... | {
"compound": "CNM-Au8",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT01994109 | Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects | PHASE3 | COMPLETED | INTERVENTIONAL | false | Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC | This study will evaluate the efficacy and safety of MYOBLOC in the treatment of Sialorrhea (drooling), which can be a symptom of many disease conditions. MYOBLOC will be injected directly into the salivary glands. MYOBLOC has been shown in previous trials to safely decrease saliva production, thereby demonstrating its ... | [
{
"type": "DRUG",
"name": "MYOBLOC"
},
{
"type": "OTHER",
"name": "PLACEBO"
}
] | 2013-11 | https://clinicaltrials.gov/study/NCT01994109 | [
"botulinum_toxin"
] | [
{
"facility": "",
"city": "Loma Linda",
"state": "California",
"country": "United States",
"status": "",
"lat": 34.04835,
"lon": -117.26115
},
{
"facility": "",
"city": "Los Angeles",
"state": "California",
"country": "United States",
"status": "",
"lat": 34.0... | {
"criteria": "Inclusion Criteria:\n\n* Seeking treatment for troublesome sialorrhea for at least 3 months that is occurring secondary to any disorder or related to any cause\n* Investigator sites will review entire list of inclusion criteria with potential subjects\n\nExclusion Criteria:\n\n* Any known prior exposur... | {
"compound": "MYOBLOC",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05923905 | Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients | PHASE4 | RECRUITING | INTERVENTIONAL | false | Peking University Third Hospital | This is a randomized double-blind controlled exploratory clinical study to evaluate the efficacy and safety of FB1006 in the treatment of amyotrophic lateral sclerosis (ALS) patients. | [
{
"type": "DRUG",
"name": "FB1006"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2023-01-18 | https://clinicaltrials.gov/study/NCT05923905 | [
"fb1006"
] | [
{
"facility": "Peking University Third Hospital",
"city": "Beijing",
"state": "Beijing Municipality",
"country": "China",
"status": "RECRUITING",
"lat": 39.9075,
"lon": 116.39723
}
] | +86-10-82265791 | scdoctor@qq.com | {
"criteria": "Inclusion Criteria:\n\n1. World Federation of Neurology modified El Ecorial criteria for diagnosis of patients with laboratory support probable, clinically probable, or definite sporadic and familial amyotrophic lateral sclerosis (ALS)\n2. Age 18 to 80 years old\n3. ALS duration no longer than 18 month... | {
"compound": "FB1006",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT07413718 | Inspiratory Muscle Training in Amiotrophyc Lateral Sclerosis | NA | RECRUITING | INTERVENTIONAL | false | University Ramon Llull | Amyotrophic Lateral Sclerosis (ALS) progressively damages the nerve cells responsible for voluntary muscle movement. Over time, this leads to weakness in different muscles such as those used for movement or breathing. Breathing problems are one of the main causes of complications and reduced survival in people with ALS... | [
{
"type": "DEVICE",
"name": "Inspiratory muscle training"
},
{
"type": "DEVICE",
"name": "Sham training"
}
] | 2025-09-01 | https://clinicaltrials.gov/study/NCT07413718 | [
"respiratory_muscle_function"
] | [
{
"facility": "ADELA Gipuzkoa",
"city": "Donostia / San Sebastian",
"state": "Gipuzka",
"country": "Spain",
"status": "RECRUITING",
"lat": 43.31283,
"lon": -1.97499
}
] | +34666580946 | jordi.gestos@gmail.com | {
"criteria": "Inclusion Criteria:\n\n* Patients diagnosed with spinal ALS\n* men and women\n* diagnosis date less than two years ago, according to the \"El Escorial\" criteria (Appendix 2)\n* PIM above the lower limit of normal\n* Preserved lung function (FVC ≥ 80%, FEV1 ≥ 80%, FEV1/FVC ≥ 80%) and normal values in s... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT00036413 | A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | Novartis Pharmaceuticals | This study is the first to be performed in Amyotrophic Lateral Sclerosis (ALS) patients with the novel compound TCH346. Its purpose is to evaluate the safety and clinical effects of 3 dose levels of TCH 346 compared to placebo in patients with a clinical diagnosis of laboratory-supported probable, probable or definite ... | [
{
"type": "DRUG",
"name": "TCH346"
}
] | 2002-01 | https://clinicaltrials.gov/study/NCT00036413 | [
"tch346"
] | [
{
"facility": "Neurological Institute",
"city": "New York",
"state": "New York",
"country": "United States",
"status": "",
"lat": 40.71427,
"lon": -74.00597
}
] | {
"criteria": "* clinical diagnosis of laboratory-supported probable, probable, or definite ALS;\n* have sporadic or familial ALS;\n* have shown ALS symptom onset for no more than 3 yrs., inclusive, prior to randomization;\n* FVC of \\>60%;\n* ability to tolerate MRS evaluation",
"sex": "ALL",
"min_age": "40 Year... | {
"compound": "TCH346",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03214146 | Safety/Efficacy Study of 2nd Cycle Treatment After 6 Months of 1st Cycle HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in ALS | PHASE1 | UNKNOWN | INTERVENTIONAL | false | Hanyang University Seoul Hospital | The purpose of this study is to evaluate the safety and efficacy of HLA-haplo matched Allogenic Bone Marrow Derived stem cells("HYNRCS-Allo-ALS-02 inj"), through intrathecal delivery for the repeated treatment after 6 months of first treatment in patients with amyotrophic lateral sclerosis(ALS).
This study is an open ... | [
{
"type": "BIOLOGICAL",
"name": "HYNRCS-Allo inj"
}
] | 2017-02-01 | https://clinicaltrials.gov/study/NCT03214146 | [
"stem_cell_therapy"
] | [
{
"facility": "Hanyang University Seoul Hospital, Cell Therapy Center for Neurologic Disorders",
"city": "Seoul",
"state": "Haengdang-dong, Seongdong-gu",
"country": "South Korea",
"status": "",
"lat": 37.566,
"lon": 126.9784
}
] | {
"criteria": "Inclusion Criteria:\n\n* Patients between 25 and 80 years old\n* Patients diagnosed as 'Possible with lab-supported' or 'Possible' or 'Probable' or 'Definite' ALS according to the World Federation of Neurology El Escorial criteria\n* Patients whose duration of disease is within 5 years from the first d... | {
"compound": "HYNRCS-Allo inj",
"targeting_mechanism": "Allogenic bone marrow derived stem cells delivered intrathecally to provide neuroprotection and promote motor neuron survival.",
"targeting_mechanism_pmid": "31189354",
"animal_results": "Preclinical stem cell studies performed in mouse and rat ALS models... | ||
NCT01835782 | Determining the Safety of L-serine in ALS | PHASE1, PHASE2 | UNKNOWN | INTERVENTIONAL | false | Phoenix Neurological Associates, LTD | The purpose of this study is to determine the safety of L-Serine in subjects with Amyotrophic Lateral Sclerosis (ALS) at varied doses. | [
{
"type": "DRUG",
"name": "L-Serine"
}
] | 2013-01 | https://clinicaltrials.gov/study/NCT01835782 | [
"serine_synthesis_pathway"
] | [
{
"facility": "Phoenix Neurological Associates",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Forbes Norris MDA/ALS Research Center",
"city": "San Francisco",
"state": "California",
... | {
"criteria": "Inclusion Criteria:\n\n1. Age 18-85\n2. Male or Female\n3. Clinically diagnosed with probable or definite ALS based on El Escorial criteria\n4. ALSFRS-R \\> 25\n5. Able to provide informed consent to and comply with all medical procedures\n\nExclusion Criteria:\n\n1. Outside age range of 18-85\n2. Subj... | {
"compound": "L-Serine",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07290062 | A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS) | PHASE1 | RECRUITING | INTERVENTIONAL | false | Insmed Gene Therapy LLC | The primary objective of this dose-finding study is to evaluate the safety, tolerability and pharmacodynamics of single dose of INS1202 via IT administration in participants ≥ 18 to \<80 years of age with ALS who carry superoxide dismutase type 1 (SOD1) mutations or harbor no known ALS-related genetic mutation. | [
{
"type": "GENETIC",
"name": "INS1202"
}
] | 2026-01-09 | https://clinicaltrials.gov/study/NCT07290062 | [
"SOD1"
] | [
{
"facility": "USA004",
"city": "La Jolla",
"state": "California",
"country": "United States",
"status": "RECRUITING",
"lat": 32.84727,
"lon": -117.2742
},
{
"facility": "USA002",
"city": "Palo Alto",
"state": "California",
"country": "United States",
"status": "R... | 1-844-446-7633 | medicalinformation@insmed.com | {
"criteria": "Key Inclusion Criteria: -\n\n* Participant with body mass index (BMI) ≥18 kilograms per square meter (kg/m\\^2).\n* Participant with symptomatic ALS as diagnosed by Gold Coast diagnostic criteria.\n* Sporadic ALS cohorts: Negative testing for known monogenic mutations associated with familial ALS.\n* S... | {
"compound": "INS1202",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT04468191 | Fatigue in Patients With Amyotrophic Lateral Sclerosis | NA | WITHDRAWN | INTERVENTIONAL | false | Cara Donohue | Expiratory muscle strength training (EMST) is an emerging palliative intervention for prolonging pulmonary and swallow function in patients with amyotrophic lateral sclerosis (PALS), but it is unknown whether EMST may result in detrimental immediate to short-term fatigue because there is no way to measure fatigue non-i... | [
{
"type": "DEVICE",
"name": "Experimental expiratory muscle strength training (EMST)"
},
{
"type": "DEVICE",
"name": "Sham expiratory muscle strength training (EMST)"
}
] | 2021-02-10 | https://clinicaltrials.gov/study/NCT04468191 | [] | [
{
"facility": "University of Pittsburgh Medical Center Presbyterian Hospital",
"city": "Pittsburgh",
"state": "Pennsylvania",
"country": "United States",
"status": "",
"lat": 40.44062,
"lon": -79.99589
}
] | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of ALS defined as possible, probable, or definite by a neurologist using the El Escorial criteria\n* FVC\\>65% predicted\n* adequate cognition as defined by a score of \\>10 on the ALS Cognitive Behavioral Screen\n* adequate labial seal for completing pulmonary functi... | {
"compound": "Expiratory muscle strength training (EMST)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT05299372 | Telemonitoring in NIV MND (OptNIVent) | NA | UNKNOWN | INTERVENTIONAL | false | Liverpool University Hospitals NHS Foundation Trust | This is a feasibility study of telemonitoring system for people with MND/ALS, who are on NIV, via a call centre operated by a local clinical commissioning group. | [
{
"type": "OTHER",
"name": "Telemonitoring via Careportal®"
}
] | 2022-04-25 | https://clinicaltrials.gov/study/NCT05299372 | [] | [] | 0151529 | hikari.ando@nhs.net | {
"criteria": "Inclusion Criteria (Patients):\n\n* Confirmed diagnosis of MND with respiratory muscle weakness\n* Adults who are capable of informed consent\n* Patients for whom we anticipate survival of 6 months or more\n* Able to communicate with an interviewer. Alternative communication methods will be used as req... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT06392126 | Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS | PHASE1, PHASE2 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | n-Lorem Foundation | This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10 | [
{
"type": "DRUG",
"name": "nL-CHCHD-001"
}
] | 2024-04-16 | https://clinicaltrials.gov/study/NCT06392126 | [
"CHCHD10"
] | [
{
"facility": "Mayo Clinic",
"city": "Jacksonville",
"state": "Florida",
"country": "United States",
"status": "",
"lat": 30.33218,
"lon": -81.65565
}
] | {
"criteria": "Inclusion Criteria:\n\n* Informed consent/assent provided by the participant (when appropriate), and/or participant's parent(s) or legally authorized representative(s).\n* Ability to travel to the study site and adhere to study-related follow-up examinations and/or procedures and provide access to part... | {
"compound": "nL-CHCHD-001",
"targeting_mechanism": "Antisense oligonucleotide targeting CHCHD10 to modulate expression of the pathogenic protein variant",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ... | ||
NCT01449578 | Dexpramipexole SAD/MAD Study | PHASE1 | COMPLETED | INTERVENTIONAL | false | Knopp Biosciences | This Phase 1 study will explore the safety, tolerability, and pharmacokinetics of single doses ranging from 300 to 600 mg and multiple daily doses ranging from 225 mg to 300 mg BID dexpramipexole in healthy volunteers. | [
{
"type": "DRUG",
"name": "Dexpramipexole"
},
{
"type": "DRUG",
"name": "Dexpramipexole Placebo"
}
] | 2011-11 | https://clinicaltrials.gov/study/NCT01449578 | [
"oxidative_stress"
] | [
{
"facility": "Research Site",
"city": "Overland Park",
"state": "Kansas",
"country": "United States",
"status": "",
"lat": 38.98223,
"lon": -94.67079
}
] | {
"criteria": "Inclusion Criteria:\n\n* Must give written informed consent.\n* Adult males/females aged 18 to 55 years inclusive and between 19 and 30 kg/m2 body mass index (BMI), inclusive at screening.\n* Subjects who are healthy as determined by prestudy medical history, physical examination and 12-lead ECG.\n* Su... | {
"compound": "Dexpramipexole",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00140218 | R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Bennett, James P., Jr., M.D., Ph.D. | The hypothesis of this study is that treatment with R(+) pramipexole at 30 mg/day will alter the slope of decline in ALS functional rating scale over the course of 6 months. ALS patients at an early stage of disease will be observed for 3 months after enrollment and then treated with drug for 6 months. | [
{
"type": "DRUG",
"name": "R(+) pramipexole dihydrochloride monohydrate"
}
] | 2005-08 | https://clinicaltrials.gov/study/NCT00140218 | [
"oxidative_stress"
] | [
{
"facility": "David Lacomis MD",
"city": "Pittsburgh",
"state": "Pennsylvania",
"country": "United States",
"status": "",
"lat": 40.44062,
"lon": -79.99589
},
{
"facility": "University of Virginia",
"city": "Charlottesville",
"state": "Virginia",
"country": "United S... | {
"criteria": "Inclusion Criteria:\n\n* established diagnosis of ALS FVC\\>60% of predicted not being ventilated no difficulty swallowing ambulatory (can use assistance devices)\n\nExclusion Criteria:\n\n* ALS duration \\>3 years advanced ALS with survival predicted \\<6 months dementia (MMSE\\<22) prior exposure to ... | {
"compound": "R(+) pramipexole dihydrochloride monohydrate",
"targeting_mechanism": "Dopamine agonist with antioxidant and neuroprotective properties targeting oxidative stress in motor neurons",
"targeting_mechanism_pmid": "34663413",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_fro... | ||
NCT03377309 | Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients | PHASE2 | TERMINATED | INTERVENTIONAL | false | American University of Beirut Medical Center | Amyotrophic lateral sclerosis (ALS), the most common motor neuron disease, is a fatal progressive neurodegenerative disease affecting motor cortex, brainstem and spinal cord leading to motor neuron death. It is a devastating disease of the anterior and lateral corticospinal tracts with approximately 3 years mean durati... | [
{
"type": "DRUG",
"name": "Fycompa"
}
] | 2019-12-01 | https://clinicaltrials.gov/study/NCT03377309 | [
"GRIN2B"
] | [
{
"facility": "Johnny S. Salameh",
"city": "Beirut",
"state": "",
"country": "Lebanon",
"status": "",
"lat": 33.89332,
"lon": 35.50157
}
] | {
"criteria": "Inclusion Criteria:\n\n* Amyotrophic Lateral Sclerosis (ALS) volunteers must be diagnosed within the 3 years prior to participation as having possible, probable, or definite ALS, either sporadic or familial according to modified El Escorial criteria\n* Age 18-80, able to provide informed consent, and c... | {
"compound": "Fycompa (perampanel)",
"targeting_mechanism": "AMPA receptor antagonist that blocks excitotoxic neuronal death pathways in motor neurons",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06126315 | Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS | PHASE2, PHASE3 | RECRUITING | INTERVENTIONAL | false | Mario Negri Institute for Pharmacological Research | Phase II/III multicenter, randomized, double-blind, placebo-controlled trial on acetyl-L-carnitine (ALCAR) in subjects living with amyotrophic lateral sclerosis (ALS). Primary study aim: The clinical objective consists of assessing the efficacy of ALCAR (two different dosages will be tested: 1.5g/day and 3g/day) on the... | [
{
"type": "DRUG",
"name": "Acetyl-l-carnitine"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2025-03-26 | https://clinicaltrials.gov/study/NCT06126315 | [
"mitochondrial_function"
] | [
{
"facility": "Concord Hospital",
"city": "Sydney",
"state": "",
"country": "Australia",
"status": "RECRUITING",
"lat": -33.86785,
"lon": 151.20732
},
{
"facility": "Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Dipartimento di Neurologia",
"city": "Bergamo",
... | 00390239014605 | elisabetta.pupillo@marionegri.it | {
"criteria": "Inclusion Criteria:\n\n1. Age 18+;\n2. ALS diagnosis according to the Gold Coast Criteria;\n3. Disease duration \\< 24 months from symptom onset, as indicated by limb weakness or bulbar symptoms, at the randomization/baseline visit\\*;\n4. Self-sufficiency \\[Satisfactory bulbar and spinal function (sc... | {
"compound": "Acetyl-L-carnitine (ALCAR)",
"targeting_mechanism": "Enhances mitochondrial bioenergetics and ATP production to support neuronal energy metabolism and reduce mitochondrial dysfunction",
"targeting_mechanism_pmid": "35805131",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed... |
NCT06147843 | French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis | NA | RECRUITING | INTERVENTIONAL | false | University Hospital, Limoges | Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. Studies have shown the importance of weight loss at the time of diagnosis and during the progression of the disease. However, the pathophysiological mechanisms behind weight loss remain unknown. Identifying these mechanisms could make it possible to pr... | [
{
"type": "OTHER",
"name": "Blood sample"
}
] | 2024-09-17 | https://clinicaltrials.gov/study/NCT06147843 | [] | [
{
"facility": "CHU de Lille",
"city": "Lille",
"state": "",
"country": "France",
"status": "RECRUITING",
"lat": 50.63391,
"lon": 3.05512
},
{
"facility": "Limoges University Hospital",
"city": "Limoges",
"state": "",
"country": "France",
"status": "RECRUITING",
... | 05 55 05 15 69 | philippe.couratier@chu-limoges.fr | {
"criteria": "Inclusion Criteria:\n\n* Incident cases included at the time of diagnosis with a definite, probable, probable laboratory-supported, or possible ALS according to El Escorial revised criteria and Gold Coast criteria for early diagnosis.\n* Incident ALS cases identified and followed-up in the participant ... | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT04798378 | NuroSleeve Powered Brace & Stimulation System to Restore Arm Function | NA | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | Thomas Jefferson University | The purpose of this study is to investigate if a person with weakness or paralysis in one or both arms, can use the NuroSleeve combined powered arm brace (orthosis) and muscle stimulation system to help restore movement in one arm sufficient to perform daily activities. This study could lead to the development of a pro... | [
{
"type": "DEVICE",
"name": "Neurosleeve"
}
] | 2020-04-16 | https://clinicaltrials.gov/study/NCT04798378 | [] | [
{
"facility": "Nemours Children's Hospital",
"city": "Wilmington",
"state": "Delaware",
"country": "United States",
"status": "",
"lat": 39.74595,
"lon": -75.54659
},
{
"facility": "Thomas Jefferson University",
"city": "Philadelphia",
"state": "Pennsylvania",
"countr... | {
"criteria": "Inclusion Criteria:• Must be 4 years or older\n\n* Must have weakness in one or both arms such that flexion or extension of the wrist, elbow or shoulder are 3/5 or less on the Manual Muscle Testing Scale\n* The etiology of weakness is due to a neurological disease or injury or orthopedic condition that... | {
"compound": "NuroSleeve (powered orthosis with muscle stimulation system)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04090684 | Ciprofloxacin/Celecoxib Combination in Patients With ALS | PHASE1 | COMPLETED | INTERVENTIONAL | false | NeuroSense Therapeutics Ltd. | This is an open label, off label study, to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability, routine disease progression measures (ALSFRS-R and Vital Capacity). | [
{
"type": "DRUG",
"name": "Fixed dose combination Ciprofloxacin/Celecoxib"
}
] | 2019-12-09 | https://clinicaltrials.gov/study/NCT04090684 | [
"neuroinflammation",
"COX2"
] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Able to comprehend and willing to sign an Informed Consent Form (ICF)\n2. Males or females between the ages of 18 and 75 years of age, inclusive\n3. Diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-supported probable, probable, or definite cri... | {
"compound": "Ciprofloxacin/Celecoxib fixed dose combination",
"targeting_mechanism": "Reduction of neuroinflammation through antibiotic and anti-inflammatory mechanisms.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_fr... | ||
NCT01605006 | Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis | NA | COMPLETED | INTERVENTIONAL | false | Synapse Biomedical | This post-approval study will follow 60 participants who have ALS, documented chronic hypoventilation, and bilateral phrenic nerve function, and who undergo the surgical implantation procedure to receive the NeuRx Diaphragm Pacing System device. Participants who are successfully implanted with the device will use it fo... | [
{
"type": "DEVICE",
"name": "NeuRx Diaphragm Pacing System (DPS)"
}
] | 2012-07 | https://clinicaltrials.gov/study/NCT01605006 | [] | [
{
"facility": "Cedars-Sinai Medical Center",
"city": "Los Angeles",
"state": "California",
"country": "United States",
"status": "",
"lat": 34.05223,
"lon": -118.24368
},
{
"facility": "California Pacific Medical Center -- Forbes Norris MDA/ALS Research Center",
"city": "San ... | {
"criteria": "Inclusion Criteria:\n\n1. Age 21 or older.\n2. Participants with familial or sporadic ALS diagnosed as laboratory-supported probable, probable, or definite according to the World Federation of Neurology El Escorial criteria.\n3. Bilateral phrenic nerve function clinically acceptable as demonstrated by ... | {
"compound": "NeuRx Diaphragm Pacing System (DPS)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT03883581 | Impact of Nuedexta on Bulbar Physiology and Function in ALS | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | University of Florida | Nuedexta is FDA approved for the treatment of pseudobulbar affect in ALS patients and anecdotal reports of improvements in speech, salivation or swallowing have been reported. However, no prospective study has been conducted to comprehensively examine and determine the physiologic impact of Nuedexta on both speech and ... | [
{
"type": "DRUG",
"name": "dextromethorphan HBr and quinidine sulfate"
}
] | 2019-07-25 | https://clinicaltrials.gov/study/NCT03883581 | [
"pseudobulbar_affect"
] | [
{
"facility": "Phil Smith Neuroscience Institute at Holy Cross Hospital",
"city": "Fort Lauderdale",
"state": "Florida",
"country": "United States",
"status": "",
"lat": 26.12231,
"lon": -80.14338
},
{
"facility": "University of Florida",
"city": "Gainesville",
"state": "... | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of probable-definite ALS (El-Escorial Criterion);\n* ALSFRS-R Bulbar subscale score \\<10\n* Bamboo oral reading speaking rate \\<140 words per minute\n* No allergies to barium sulfate.\n\nExclusion Criteria:\n\n* Treatment for sialorrhea within the past 3 months that... | {
"compound": "dextromethorphan HBr and quinidine sulfate",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT01486849 | Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Cytokinetics | A Phase II, double-blind, randomized, placebo-controlled ascending dose titration study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic effects of multiple ascending doses of CK-2017357 to an individual patient maximum tolerated dose (MTD), using a within-patient twice daily (BID) dose-titrat... | [
{
"type": "DRUG",
"name": "CK-2017357"
},
{
"type": "DRUG",
"name": "Placebo"
},
{
"type": "DRUG",
"name": "Riluzole 50 MG"
}
] | 2011-11 | https://clinicaltrials.gov/study/NCT01486849 | [
"muscle_contractility"
] | [
{
"facility": "University of California at San Francisco, Fresno Campus, Central California Neurological Institute",
"city": "Fresno",
"state": "California",
"country": "United States",
"status": "",
"lat": 36.74773,
"lon": -119.77237
},
{
"facility": "Coordinated Clinical Resear... | {
"criteria": "Inclusion Criteria:\n\n1. Able to comprehend and willing to sign an Informed Consent Form (ICF)\n2. Males or females 18 years of age or older\n3. A diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of AL... | {
"compound": "CK-2017357",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04952155 | Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome | PHASE2 | UNKNOWN | INTERVENTIONAL | false | Peking University Third Hospital | The purpose of this study was to evaluate the efficacy and safety of low-dose IL-2 in the treatment of immunorelated ALS syndrome. | [
{
"type": "DRUG",
"name": "IL-2"
}
] | 2020-01-01 | https://clinicaltrials.gov/study/NCT04952155 | [
"IL-2"
] | [
{
"facility": "Peking University Third Hospital",
"city": "Beijing",
"state": "Beijing Municipality",
"country": "China",
"status": "RECRUITING",
"lat": 39.9075,
"lon": 116.39723
}
] | +86 13701023871 | dsfan@sina.com | {
"criteria": "Inclusion Criteria:\n\n* 18-70 years old;\n* Clinically diagnosed with ALS syndrome, i.e., with ALS -like manifestations, consisting of a combination of upper and/or lower motor neuron damage;\n* significant abnormalities with rheumatoid immune-related indicators, or diagnoses of immune-mediated ALS sy... | {
"compound": "IL-2",
"targeting_mechanism": "Modulation of adaptive immune response through interleukin-2 signaling to treat immune-associated ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT00070993 | Creatine for the Treatment of Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | National Center for Complementary and Integrative Health (NCCIH) | Creatine is a naturally occurring chemical involved in the production of energy in muscle. Abnormalities in creatine have been linked to the progression of degenerative neuromuscular diseases such as amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease). This study will test whether taking creatine can improve t... | [
{
"type": "DRUG",
"name": "creatine monohydrate"
}
] | 2002-12 | https://clinicaltrials.gov/study/NCT00070993 | [
"cellular_energy_metabolism"
] | [
{
"facility": "California Pacific Medical Center",
"city": "San Francisco",
"state": "California",
"country": "United States",
"status": "",
"lat": 37.77493,
"lon": -122.41942
},
{
"facility": "Rush-Presbyterian St. Luke's Medical Center",
"city": "Chicago",
"state": "Ill... | {
"criteria": "Inclusion Criteria\n\n* Diagnosis of probable or definite ALS\n* At least 5 of 10 testable upper extremity muscle groups (shoulder and elbow extensors/flexors and grip) of Medical Research Council (MRC) grade 4 or better\n* At least 5 years from onset of symptoms\n\nExclusion Criteria\n\n* Requires tra... | {
"compound": "creatine monohydrate",
"targeting_mechanism": "Creatine enhances energy production in muscle by supporting ATP synthesis and cellular energy homeostasis in motor neurons.",
"targeting_mechanism_pmid": "29549424",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not ... | ||
NCT03892863 | Repetitive Transcranial Magnetic Stimulation as Therapy for Depression in Amyotrophic Lateral Sclerosis | NA | WITHDRAWN | INTERVENTIONAL | false | Jagiellonian University | Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive loss of central and peripheral motor neurons. ALS leads to death usually within 3 to 5 years from the onset of the symptoms. Available treatment can prolong the disease duration but cannot modify the disease course. Depressi... | [
{
"type": "DEVICE",
"name": "active repetitive transcranial magnetic stimulation"
},
{
"type": "DEVICE",
"name": "sham repetitive transcranial magnetic stimulation"
}
] | 2019-11-15 | https://clinicaltrials.gov/study/NCT03892863 | [] | [
{
"facility": "Jagiellonian University Medical College, Department of Neurology",
"city": "Krakow",
"state": "",
"country": "Poland",
"status": "",
"lat": 50.06143,
"lon": 19.93658
}
] | {
"criteria": "Inclusion Criteria:\n\n* Diagnosis of definite or probable ALS according to el Escorial criteria (Brooks et al. 2000)\n* Depression defined as the score in Beck's Depression Inventory ≥14\n* Mini-Mental State Examination score ≥26\n\nExclusion Criteria:\n\n* Psychiatric symptoms, which may negatively i... | {
"compound": "repetitive transcranial magnetic stimulation",
"targeting_mechanism": "Repetitive transcranial magnetic stimulation modulates upper motor neuron excitability and corticomotor function.",
"targeting_mechanism_pmid": "37068329",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurpose... | ||
NCT06119087 | Mechanical Insufflation in the Philadelphia Amyotrophic Lateral Sclerosis Cohort (MI-PALS) Study | NA | COMPLETED | INTERVENTIONAL | false | University of Pennsylvania | The goal of this clinical trial is to learn how doing mechanical insufflation (MI) using a mechanical insufflator-exsufflator (MI-E) device affects breathing in early amyotrophic lateral sclerosis (ALS). This will be a single-center, single-arm study of MI in 20 patients with ALS at Penn.
Based on prior research, we b... | [
{
"type": "DEVICE",
"name": "Mechanical insufflation"
}
] | 2024-09-12 | https://clinicaltrials.gov/study/NCT06119087 | [] | [
{
"facility": "University of Pennsylvania",
"city": "Philadelphia",
"state": "Pennsylvania",
"country": "United States",
"status": "",
"lat": 39.95238,
"lon": -75.16362
}
] | {
"criteria": "Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. Age ≥18 years.\n4. Diagnosed with amyotrophic lateral sclerosis using the Gold Coast Criteria.\n5. Have an able a... | {
"compound": "mechanical insufflation",
"targeting_mechanism": "Mechanical insufflation augments respiratory muscle function by using a mechanical insufflator-exsufflator device to assist breathing and cough clearance.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
... | ||
NCT02487407 | Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | Orion Corporation, Orion Pharma | In the double-blind, cross-over part of the study, ODM-109 capsules and placebo capsules for ODM-109 will be administered for 2 weeks separated by a 19-23 days wash-out period. During each treatment period of the double-blind cross-over part, there will be a baseline visit (day 1) and 2 visits (5 ± 2 and 14 ± 2 days) a... | [
{
"type": "DRUG",
"name": "ODM-109"
},
{
"type": "DRUG",
"name": "Placebo for ODM-109"
}
] | 2015-07 | https://clinicaltrials.gov/study/NCT02487407 | [
"respiratory_function"
] | [
{
"facility": "Charite Universitatsmedizin Berlin",
"city": "Berlin",
"state": "",
"country": "Germany",
"status": "",
"lat": 52.52437,
"lon": 13.41053
},
{
"facility": "Medical School Hannover",
"city": "Hanover",
"state": "",
"country": "Germany",
"status": "",
... | {
"criteria": "Inclusion Criteria:\n\n* Written informed consent (IC) for participation in the study will be obtained from the subject (or from the subject's next of kin, caregiver, or other legally acceptable representative in case the study subject him/herself cannot sign the IC due to severe muscle weakness).\n* A... | {
"compound": "ODM-109",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03809845 | Serial Fasciculation Measurements in Motor Neurone Disease | NA | COMPLETED | INTERVENTIONAL | false | King's College Hospital NHS Trust | Patients with motor neurone disease (MND) typically experience relentless motor decline and die within three years of symptom onset from respiratory muscle weakness. There are currently no effective therapies and the discovery of novel therapies is hampered by the lack of a sensitive disease biomarker. Consequently, th... | [
{
"type": "DEVICE",
"name": "High-density surface electromyography"
}
] | 2017-07-06 | https://clinicaltrials.gov/study/NCT03809845 | [] | [
{
"facility": "King's College Hospital NHS Foundation Trust",
"city": "London",
"state": "",
"country": "United Kingdom",
"status": "",
"lat": 51.50853,
"lon": -0.12574
}
] | {
"criteria": "Inclusion criteria for MND patients:\n\n(i) Aged between 40 and 80 years of age inclusive, at the time of signing the informed consent.\n\n(ii) Diagnosed with MND by a neurologist with expertise in MND.(20) For subjects with bulbar onset there must be objective limb involvement of at least one limb.\n\... | {
"compound": "high-density surface electromyography",
"targeting_mechanism": "High-density surface electromyography is a non-invasive diagnostic and monitoring tool that measures motor unit activity to track motor neuron degeneration.",
"targeting_mechanism_pmid": "28043769",
"animal_results": "unknown",
"an... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.